What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2020-08-07 compared with 2020-02-13 · 2387 added, 919 removed, 169 unchanged (95% of the section changed)

Investing in our common stock involves a high degree of risk.

You should carefully consider the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q, including our consolidated financial statements and related notes and Managements discussion and analysis of results of operations and financial condition. If any of the following risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected.

In that event, the price of our common stock could decline, and you could lose part or all of your investment.

The risks and uncertainties described below are not the only ones we face.

Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.

Investing in our common stock involves

a high degree of risk.

You should carefully consider the risks and uncertainties described below, together with all of the other

information in this Quarterly Report on Form 10-Q, including our consolidated financial statements and related notes and “Management’s

discussion and analysis of results of operations and financial condition.”

If any of the following risks are realized, our

business, financial condition, operating results and prospects could be materially and adversely affected.

In that event, the price

of our common stock could decline, and you could lose part or all of your investment.

The risks and uncertainties described below

are not the only ones we face.

Additional risks and uncertainties not presently known to us or that we currently believe to be

immaterial may also adversely affect our business.

Risks related to product development

Our product candidates are in the early stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable.

We have never generated any revenue from product sales and may never be profitable.

All of our product candidates are in research or early development.

We have not generated any revenues from the sale of products and do not expect to do so for at least the next several years.

Our lead product candidate, RP1, and any other product candidates will require extensive preclinical and/or clinical testing and regulatory approval prior to commercial use.

Our product candidates are in the early stages of development,

are not approved for commercial sale and might never receive regulatory approval or become commercially viable.

We have never generated

any revenue from product sales and may never be profitable.

All of our product candidates are in research

or early development.

We have not generated any revenues from the sale of products and do not expect to do so for at least the

next several years.

Our lead product candidate, RP1, and any other product candidates will require extensive preclinical and/or

clinical testing and regulatory approval prior to commercial use.

Our research and development efforts may not be successful.

Even if our clinical development efforts result in positive data, our product candidates may not receive regulatory approval or be successfully introduced and marketed at prices that would permit us to operate profitably.

We currently have only two product candidates in clinical development.

A failure of these product candidate in clinical development would adversely affect our business and may require us to discontinue development of other product candidates based on the same or similar therapeutic approaches.

RP1 and RP2 are our only clinical development-stage product candidates.

Although we have another product candidate, RP3, in preclinical development and we may develop additional product candidates in the coming years, it will take additional investment and time for such product candidates to reach the same stage of development as those that are in clinical development, and there can be no assurance that they will ever do so.

Since all of the product candidates in our current pipeline are based on our Immulytic platform, if RP1 fails in development as a result of any underlying problem with our Immulytic platform, then we may be required to discontinue development of all product candidates that are based on our therapeutic approach.

If we were required to discontinue development of RP1, RP2 or our other product candidates, or if any of them were to fail to receive regulatory approval or achieve sufficient market acceptance, we could be prevented from or significantly delayed in achieving profitability.

We can provide no assurance that we would be successful at developing other product candidates based on an alternative therapeutic approach.

We will not be able to commercialize our product candidates if our preclinical studies do not produce successful results and/or our clinical trials do not demonstrate the safety and efficacy of our product candidates.

Our lead product candidate, RP1, is in an ongoing Phase 1/2 clinical trial alone and in combination with nivolumab and we have initiated a Phase 2 clinical trial of RP1 in combination with cemiplimab in CSCC.

We also expect to enroll approximately 30 patients in a Phase 1 clinical trial of RP1 alone in organ transplant recipients with CSCC with the clinical trial expected to initiate in the first quarter of 2020.

Additionally, RP2, the next product candidate from our Immulytic platform, is in an ongoing Phase 1/2 clinical trial alone and in combination with nivolumab.

Our third product candidate, RP3, is in preclinical development, which we expect to enter clinical development in 2020.

Our product candidates will require preclinical and/or clinical trials before we can submit a marketing application to the applicable regulatory authorities.

Our product candidates are susceptible to the risks of failure inherent at any stage of product development, including the occurrence of unexpected or unacceptable adverse events or the failure to demonstrate efficacy in clinical trials.

Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain.

The results of preclinical studies, preliminary study results, and early clinical trials of our product candidates may not be predictive of the results of later stage clinical trials.

Our product candidates may not perform as we expect, may ultimately have a different or no impact on tumors, may have a different mechanism of action than we expect in humans, and may not ultimately prove to be safe and effective.

Preliminary and final results from preclinical studies and early stage trials, and trials in compounds that we believe are similar to ours, may not be representative of results that are found in larger, controlled, blinded, and longer term studies.

Product candidates may fail at any stage of preclinical or clinical development.

Product candidates may fail to show the desired safety and efficacy traits even if they have progressed through preclinical studies or initial clinical trials.

Preclinical studies and clinical trials may also reveal unfavorable product candidate characteristics, including safety concerns.

A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials, notwithstanding promising results in earlier preclinical studies or clinical trials or promising mechanisms of action.

In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols

and the rate of dropout among clinical trial participants.

if our clinical development efforts result in positive data, our product candidates may not receive regulatory approval or be successfully

introduced and marketed at prices that would permit us to operate profitably.

We currently have only two product candidates in clinical

A failure of these product candidates in clinical development would adversely affect our business and may require

us to discontinue development of other product candidates based on the same or similar therapeutic approaches.

RP1 and RP2 are our only clinical development-stage

product candidates.

Although we have another product candidate, RP3, in preclinical development and we may develop additional product

candidates in the coming years, it will take additional investment and time for such product candidates to reach the same stage

of development as those that are in clinical development, and there can be no assurance that they will ever do so.

the product candidates in our current pipeline are based on our Immulytic platform, if RP1 fails in development as a result of

any underlying problem with our Immulytic platform, then we may be required to discontinue development of all product candidates

that are based on our therapeutic approach.

If we were required to discontinue development of RP1, RP2 or our other product candidates,

or if any of them were to fail to receive regulatory approval or achieve sufficient market acceptance, we could be prevented from

or significantly delayed in achieving profitability.

We can provide no assurance that we would be successful at developing other

product candidates based on an alternative therapeutic approach.

We will not be able to commercialize our product candidates

if our preclinical studies do not produce successful results and/or our clinical trials do not demonstrate the safety and efficacy

of our product candidates.

Our lead product candidate, RP1, is in an

ongoing Phase 1/2 clinical trial alone and in combination with nivolumab and we have initiated a Phase 2 clinical trial of

RP1 in combination with cemiplimab in CSCC.

We have also opened for enrollment a Phase 1b clinical trial of single agent RP1 in

solid organ transplant recipients in approximately 30 patients with CSCC.

Additionally, RP2, the next product candidate from our

Immulytic platform, is in an ongoing Phase 1/2 clinical trial alone and in combination with nivolumab.

Our third product candidate,

RP3, is in preclinical development, and we expect to enter clinical development in 2020.

Our product candidates will require preclinical

and/or clinical trials before we can submit a marketing application to the applicable regulatory authorities.

Our product candidates are susceptible to

the risks of failure inherent at any stage of product development, including the occurrence of unexpected or unacceptable adverse

events or the failure to demonstrate efficacy in clinical trials.

Clinical development is expensive and can take many years to

complete, and its outcome is inherently uncertain.

The results of preclinical studies, preliminary

study results, and early clinical trials of our product candidates may not be predictive of the results of later stage clinical

Our product candidates may not perform as we expect, may ultimately have a different or no impact on tumors, may have a

different mechanism of action than we expect in humans, and may not ultimately prove to be safe and effective.

Preliminary and final results from preclinical

studies and early stage trials, and trials in compounds that we believe are similar to ours, may not be representative of results

that are found in larger, controlled, blinded, and longer-term studies.

Product candidates may fail at any stage of preclinical

or clinical development.

Product candidates may fail to show the desired safety and efficacy traits even if they have progressed

through preclinical studies or initial clinical trials.

Preclinical studies and clinical trials may also reveal unfavorable product

candidate characteristics, including safety concerns.

A number of companies in the biopharmaceutical industry have suffered significant

setbacks in clinical trials, notwithstanding promising results in earlier preclinical studies or clinical trials or promising mechanisms

In some instances, there can be significant variability in safety or efficacy results between different clinical trials

of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences

in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout

among clinical trial participants.

Moreover, should there be an issue with the design of a clinical trial, our results may be impacted.

We may not discover such a flaw until the clinical trial is at an advanced stage.

We may also experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:

· regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial, conduct a clinical trial at a prospective trial site, or amend trial protocols, or may require that we modify or amend our clinical trial protocols;

· we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and/or contract research organizations, or CROs;

· clinical trials of our product candidates may produce negative or inconclusive results, or our studies may fail to reach the necessary level of statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;

· the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or be lost to follow-up at a higher rate than we anticipate, or may elect to participate in alternative clinical trials sponsored by our competitors with product candidates that treat the same indications as our product candidates;

· our third party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring;

· we, regulators, or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks, undesirable side effects, or other unexpected characteristics of the product candidate, or due to findings of undesirable effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;

· changes could be adopted in marketing approval policies during the development period, rendering our data insufficient to obtain marketing approval;

We may also experience numerous unforeseen

events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize

our product candidates, including:

● regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial,

conduct a clinical trial at a prospective trial site, or amend trial protocols, or may require that we modify or amend our clinical

trial protocols;

● we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial

protocols with prospective trial sites and/or contract research organizations, or CROs;

● clinical trials of our product candidates may produce negative or inconclusive results, or our studies may fail to reach the

necessary level of statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials

or abandon product development programs;

● the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment

in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or be lost to follow-up

at a higher rate than we anticipate, or may elect to participate in alternative clinical trials sponsored by our competitors with

product candidates that treat the same indications as our product candidates;

● our third-party contractors may fail to comply with regulatory requirements or the clinical trial protocol, or meet their contractual

obligations to us in a timely manner, or at all, or we may be required to engage in additional clinical trial site monitoring;

● we, regulators, or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons,

including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health

risks, undesirable side effects, or other unexpected characteristics of the product candidate, or due to findings of undesirable

effects caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;

● changes could be adopted in marketing approval policies during the development period, rendering our data insufficient to obtain

marketing approval;

● statutes or regulations could be amended or new ones could be adopted;

● changes could be adopted in the regulatory review process for submitted product applications;

· the cost of clinical trials of our product candidates may be greater than we anticipate or we may have insufficient funds for a clinical trial or to pay the substantial user fees required by the FDA upon the filing of a Biologics License Application, or BLA, or equivalent authorizations from comparable foreign regulatory authorities;

· the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;

· we may decide, or regulators may require us, to conduct or gather, as applicable, additional clinical trials, analyses, reports, data, or preclinical trials, or we may abandon product development programs;

· we may fail to reach an agreement with regulators or IRBs regarding the scope, design, or implementation of our clinical trials, and the FDA or comparable foreign regulatory authorities may require changes to our study designs that make further study impractical or not financially prudent;

· regulators may ultimately disagree with the design or our conduct of our preclinical studies or clinical trials, finding that they do not support product candidate approval;

· we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial sites;

· patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the study or clinical trial, increase the needed enrollment size for the clinical trial or extend its duration;

● the cost of clinical trials of our product candidates may be greater than we anticipate or we may have insufficient funds for

a clinical trial or to pay the substantial user fees required by the FDA upon the filing of a Biologics License Application, or

BLA, or equivalent authorizations from comparable foreign regulatory authorities;

● the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates

may be insufficient or inadequate;

● we may decide, or regulators may require us, to conduct or gather, as applicable, additional clinical trials, analyses, reports,

data, or preclinical trials, or we may abandon product development programs;

● we may fail to reach an agreement with regulators or IRBs regarding the scope, design, or implementation of our clinical trials,

and the FDA or comparable foreign regulatory authorities may require changes to our study designs that make further study impractical

or not financially prudent;

● regulators may ultimately disagree with the design or our conduct of our preclinical studies or clinical trials, finding that

they do not support product candidate approval;

● we may have delays in adding new investigators or clinical trial sites, or we may experience a withdrawal of clinical trial

● patients that enroll in our studies may misrepresent their eligibility or may otherwise not comply with the clinical trial

protocol, resulting in the need to drop the patients from the study or clinical trial, increase the needed enrollment size for

the clinical trial or extend its duration;

● there may be regulatory questions or disagreements regarding interpretations of data and results;

· the FDA or comparable foreign regulatory authorities may disagree with our study design, including endpoints, or our interpretation of data from preclinical studies and clinical trials or find that a product candidates benefits do not outweigh its safety risks;

· the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign countries;

● the FDA or comparable foreign regulatory authorities may disagree with our study design, including endpoints, or our interpretation

of data from preclinical studies and clinical trials or find that a product candidate’s benefits do not outweigh its safety

● the FDA or comparable foreign regulatory authorities may not accept data from studies with clinical trial sites in foreign

● the FDA or comparable foreign regulatory authorities may disagree with our intended indications;

· the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or our manufacturing facilities for clinical and future commercial supplies;

· the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;

● the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing

processes or our manufacturing facilities for clinical and future commercial supplies;

● the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable

foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to

obtain regulatory approval in the United States or elsewhere;

● the FDA or comparable foreign regulatory authorities may take longer than we anticipate to make a decision on our product candidates;

· we may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current or future competitive therapies in development.

Our development costs will also increase if we experience delays in testing or approvals, and we may not have sufficient funding to complete the testing and approval process for any of our product candidates.

We may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates.

We do not know whether any preclinical tests or clinical trials beyond what we currently have planned will be required, will begin as planned, will need to be restructured, or will be completed on schedule, or at all.

Significant delays relating to any preclinical or clinical trials also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.

In addition, many of the factors that cause, or lead to, delays in clinical trials may ultimately lead to the denial of marketing approval of any of our product candidates.

If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed.

We anticipate that our product candidates will be used in combination with third party drugs, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs.

Our product candidates may be administered in combination with checkpoint blockade drugs, a class of drugs that are intended to stop tumor cells from switching off an immune system attack against themselves.

We have entered into an agreement with BMS for the supply of nivolumab, its anti-PD-1 therapy, for use in connection with our current Phase 1/2 clinical trials with RP1 and RP2.

We have also entered into a clinical collaboration agreement with Regeneron, which includes the supply of cemiplimab, its anti-PD-1 therapy, for clinical trials conducted under the Regeneron agreement.

We are enrolling patients in our first planned clinical trial under the agreement, a randomized, controlled Phase 2 clinical trial of RP1 in combination with cemiplimab, versus cemiplimab alone, in approximately 240 patients with CSCC.

We may enter into additional agreements for the supply of anti-PD-1 products for use in connection with the development of one or more of our product candidates.

Our ability to develop and ultimately commercialize our product candidates used in combination with nivolumab, cemiplimab or any other checkpoint blockade therapy will depend on our ability to access such drugs on commercially reasonable terms for the clinical trials and their availability for use with the commercialized product, if approved.

We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially reasonable terms or at all.

Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing checkpoint blockade therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our product candidates as commercially viable therapies.

If any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed.

Moreover, the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates.

While we are planning a new clinical trial for use of RP1 as a monotherapy, we are developing RP1 and our other product candidates for use in combination with anti-PD-1 or anti-PDL1 therapies and may develop RP1 or our other product candidates for use with other therapies.

The FDA may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects.

It is possible that the results of these trials could show that any positive previous trial results are attributable to the combination therapy and not our product candidates.

Moreover, following product approval, the FDA may require that products used in conjunction with each other be cross labeled for combined use.

To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement.

Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive marketing approval.

Such developments may include changes to the other products safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care.

In the event that BMS, Regeneron or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing an anti-PD-1 therapy.

Additionally, should the supply of products from BMS, Regeneron or any future collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed.

In the event we are unable to source a supply of an alternative anti-PD-1 therapy, or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price and prospects may be materially harmed.

If we fail to develop additional product candidates, our commercial opportunity could be limited.

● we may not be able to demonstrate that a product candidate provides an advantage over current standards of care or current

or future competitive therapies in development;

● we, the third parties on which we rely, and the FDA may have delays in the conduct of our respective operations as a result

of the effects of the COVID-19 pandemic, which could result in delays or prevent our ability to receive marketing approval or commercialize

our product candidates.

Our development costs will also increase

if we experience delays in testing or approvals, and we may not have sufficient funding to complete the testing and approval process

for any of our product candidates.

We may be required to obtain additional funds to complete clinical trials and prepare for possible

commercialization of our product candidates.

We do not know whether any preclinical tests or clinical trials beyond what we currently

have planned will be required, will begin as planned, will need to be restructured, or will be completed on schedule, or at all.

Significant delays relating to any preclinical or clinical trials also could shorten any periods during which we may have the exclusive

right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our

ability to successfully commercialize our product candidates and may harm our business and results of operations.

many of the factors that cause, or lead to, delays in clinical trials may ultimately lead to the denial of marketing approval of

any of our product candidates.

If any of these occur, our business, financial condition, results of operations, stock price and

prospects may be materially harmed.

We anticipate that our product candidates will be used

in combination with third-party drugs, some of which are still in development, and we have limited or no control over the supply,

regulatory status, or regulatory approval of such drugs.

Our product candidates may be administered

in combination with checkpoint blockade drugs, a class of drugs that are intended to stop tumor cells from “switching off”

an immune system attack against themselves.

We have entered into agreements with BMS for the supply of nivolumab, its anti-PD-1

therapy, for use in connection with our current Phase 1/2 clinical trials with RP1 and RP2.

We have also entered into a clinical

collaboration agreement with Regeneron, which includes the supply of cemiplimab, its anti-PD-1 therapy, for clinical trials conducted

We are enrolling patients in our first planned clinical trial under the Regeneron agreement, a randomized, controlled

Phase 2 clinical trial of RP1 in combination with cemiplimab, versus cemiplimab alone, in approximately 240 patients with

We may enter into additional agreements for the supply of anti-PD-1 products for use in connection with the development of

one or more of our product candidates.

Our ability to develop and ultimately commercialize our product candidates used in combination

with nivolumab, cemiplimab or any other checkpoint blockade therapy will depend on our ability to access such drugs on commercially

reasonable terms for the clinical trials and their availability for use with the commercialized product, if approved.

be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially

reasonable terms or at all.

Any failure to maintain or enter into new

successful commercial relationships, or the expense of purchasing checkpoint blockade therapies in the market, may delay our development

timelines, increase our costs and jeopardize our ability to develop our product candidates as commercially viable therapies.

any of these occur, our business, financial condition, results of operations, stock price and prospects may be materially harmed.

Moreover, the development of product candidates

for use in combination with another product or product candidate may present challenges that are not faced for single agent product

While we are planning a new clinical trial for use of RP1 as a monotherapy, we are developing RP1 and our other product

candidates for use in combination with anti-PD-1 or anti-PDL1 therapies and may develop RP1 or our other product candidates for

use with other therapies.

The FDA may require us to use more complex clinical trial designs in order to evaluate the contribution

of each product and product candidate to any observed effects.

It is possible that the results of these trials could show that

any positive previous trial results are attributable to the combination therapy and not our product candidates.

Moreover, following

product approval, the FDA may require that products used in conjunction with each other be cross-labeled for combined use.

extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement.

Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial

prospects should we receive marketing approval.

Such developments may include changes to the other product’s safety or efficacy

profile, changes to the availability of the approved product, and changes to the standard of care.

In the event that BMS, Regeneron or any

future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify

alternatives for accessing an anti-PD-1 therapy.

Additionally, should the supply of products from BMS, Regeneron or any future

collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed.

event we are unable to source a supply of an alternative anti-PD-1 therapy, or are unable to do so on commercially reasonable terms,

our business, financial condition, results of operations, stock price and prospects may be materially harmed.

If we fail to develop additional product candidates, our

commercial opportunity could be limited.

Our lead product candidate is RP1.

A key part of our strategy is to pursue clinical development of RP1 and additional product candidates, RP2 and RP3.

Developing, obtaining marketing approval for, and commercializing additional product candidates will require substantial additional funding and will be subject to the risks of failure inherent in medical product development.

We cannot assure our shareholders that we will be able to successfully advance any of these additional product candidates through the development process.

Even if we obtain approval from the FDA or comparable foreign regulatory authorities to market additional product candidates for the treatment of solid tumors, we cannot assure our shareholders that any such product candidates will be successfully commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives.

If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity may be limited and our business, financial condition, results of operations, stock price and prospects may be materially harmed.

part of our strategy is to pursue clinical development of RP1 and additional product candidates, including RP2 and RP3.

obtaining marketing approval for, and commercializing additional product candidates will require substantial additional funding

and will be subject to the risks of failure inherent in medical product development.

We cannot assure our shareholders that we

will be able to successfully advance any of these additional product candidates through the development process.

Even if we obtain approval from the FDA

or comparable foreign regulatory authorities to market additional product candidates for the treatment of solid tumors, we cannot

assure our shareholders that any such product candidates will be successfully commercialized, widely accepted in the marketplace,

or more effective than other commercially available alternatives.

If we are unable to successfully develop and commercialize additional

product candidates, our commercial opportunity may be limited and our business, financial condition, results of operations, stock

price and prospects may be materially harmed.

Risks related to regulatory approval

Even if our development efforts are successful, we may not obtain regulatory approval for any of our product candidates in the United States or other jurisdictions, which would prevent us from commercializing our product candidates.

Even if we obtain regulatory approval for our product candidates, any such approval may be subject to limitations, including with respect to the approved indications or patient populations, which could impair our ability to successfully commercialize our product candidates.

We are not permitted to market or promote or sell any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates.

Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidates safety and efficacy for that indication.

Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial sites by, the regulatory authorities.

If we do not receive approval from the FDA and comparable foreign regulatory authorities for any of our product candidates, we will not be able to commercialize such product candidates in the United States or in other jurisdictions.

If significant delays in obtaining approval for and commercializing our product candidates occur in any jurisdictions, our business, financial condition, results of operations, stock price and prospects will be materially harmed.

Even if our product candidates are approved, they may:

· be subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution restrictions, or other conditions of approval;

Even if our development efforts are successful, we may

not obtain regulatory approval for any of our product candidates in the United States or other jurisdictions, which would prevent

us from commercializing our product candidates.

Even if we obtain regulatory approval for our product candidates, any such approval

may be subject to limitations, including with respect to the approved indications or patient populations, which could impair our

ability to successfully commercialize our product candidates.

We are not permitted to market or promote

or sell any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities,

and we may never receive such regulatory approval for any of our product candidates.

Securing marketing approval requires the submission

of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication

to establish the product candidate’s safety and efficacy for that indication.

Securing marketing approval also requires the

submission of information about the product manufacturing process to, and inspection of manufacturing facilities and clinical trial

sites by, the regulatory authorities.

If we do not receive approval from the FDA and comparable foreign regulatory authorities

for any of our product candidates, we will not be able to commercialize such product candidates in the United States or in other

jurisdictions.

If significant delays in obtaining approval for and commercializing our product candidates occur in any jurisdictions,

our business, financial condition, results of operations, stock price and prospects will be materially harmed.

Even if our product

candidates are approved, they may:

● be subject to limitations on the indicated uses or patient populations for which they may be marketed, distribution restrictions,

or other conditions of approval;

● contain significant safety warnings, including boxed warnings, contraindications, and precautions;

● not be approved with label statements necessary or desirable for successful commercialization;

· contain requirements for costly postmarket testing and surveillance, or other requirements, including the submission of a risk evaluation and mitigation strategy, or REMS, to monitor the safety or efficacy of the products.

We have not previously submitted a BLA to the FDA, or a similar marketing application to comparable foreign regulatory authorities, for any product candidate, and we can provide no assurance that we will ultimately be successful in obtaining regulatory approval for claims that are necessary or desirable for successful marketing, or at all.

The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable.

If we are not able to obtain, or experience delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates as expected, and our ability to generate revenue may be materially impaired.

The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities.

In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidates clinical development and may vary among jurisdictions and there may be varying interpretations of data obtained from preclinical studies or clinical trials, any of which may cause delays or limitations in the approval or a decision not to approve an application.

These regulatory requirements may require us to amend our clinical trial protocols, conduct additional preclinical studies or clinical trials that may require regulatory or IRB approval, or otherwise cause delays in the approval or rejection of an application.

Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which may materially harm our business, financial condition, results of operations, stock price and prospects.

If we experience delays in obtaining approval, if we fail to obtain approval of a product candidate or if the label for a product candidate does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate, the commercial prospects for such product candidate may be harmed and our ability to generate revenues from that product candidate may be materially impaired.

The FDA or a comparable foreign regulatory authority may determine that our product candidates have undesirable side effects that could delay or prevent their regulatory approval or commercialization.

To date, the most commonly reported adverse events observed for RP1 are local injection site reactions and systemic constitutional symptoms, such as fatigue, fevers and chills.

However, there can be no assurance that additional undesirable side effects or serious adverse events will not be caused by or associated with RP1 or our other product candidates as they continue through or enter clinical development.

Serious adverse events or undesirable side effects caused by our product candidates could cause us, IRBs, and other reviewing entities or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities.

For example, if concerns are raised regarding the safety of a new therapeutic as a result of undesirable side effects identified during clinical or preclinical testing, the FDA or comparable foreign regulatory authority may order us to cease further development, decline to approve the product candidate or issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve the product candidate.

The FDA or comparable foreign regulatory authorities, or IRBs and other reviewing entities, may also require, or we may voluntarily develop, strategies for managing adverse events during clinical development, which could include restrictions on our enrollment criteria, the use of stopping criteria, adjustments to a studys design, or the monitoring of safety data by a data monitoring committee, among other strategies.

FDA or comparable foreign regulatory authority requests for additional data or information could also result in substantial delays in the approval of our product candidates.

Undesirable side effects caused by any of our product candidates could also result in denial of regulatory approval by the FDA or comparable foreign regulatory authorities for any or all targeted indications or the inclusion of unfavorable information in our product labeling, such as limitations on the indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization, or may result in requirements for costly postmarketing testing and surveillance, or other requirements, including REMS, to monitor the safety or efficacy of the products, and in turn prevent us from commercializing and generating revenues from the sale of our product candidates.

Undesirable side effects may limit the potential market for any approved products or could result in the discontinuation of the sales and marketing of the product, or withdrawal of product approvals.

Later discovered undesirable side effects may further result in the imposition of a REMS, label revisions, post approval study requirements, or other testing and surveillance.

If any of our product candidates is associated with serious adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective.

The therapeutic-related side effects could affect patient recruitment or the ability of enrolled patients to

complete the trial or result in potential product liability claims.

Any of these occurrences may materially harm our business, financial condition, results of operations, stock price and prospects.

Changes in product candidate manufacturing or formulation may result in additional costs or delay.

As product candidates are developed through preclinical studies to later stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results.

Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials.

Such changes may also require additional testing, or notification to, or approval by the FDA or a comparable foreign regulatory authority.

This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenue.

Regulatory approval by the FDA or comparable foreign regulatory authorities is limited to those specific indications and conditions for which approval has been granted, and we may be subject to substantial fines, criminal penalties, injunctions, or other enforcement actions if we are determined to be promoting the use of our products for unapproved or off label uses, resulting in damage to our reputation and business.

We must comply with requirements concerning advertising and promotion for any product candidates for which we obtain marketing approval.

Promotional communications with respect to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of Justice, Department of Health and Human Services Office of Inspector General, state attorneys general, members of Congress, and the public.

When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited to those specific uses and indications for which a product is approved.

If we are not able to obtain FDA approval for desired uses or indications for our product candidates, we may not market or promote them for those indications and uses, referred to as off label uses, and our business, financial condition, results of operations, stock price and prospects will be materially harmed.

We also must sufficiently substantiate any claims that we make for our products, including claims comparing our products to other companies products, and must abide by the FDAs strict requirements regarding the content of promotion and advertising.

While physicians may choose to prescribe products for uses that are not described in the products labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, we are prohibited from marketing and promoting the products for indications and uses that are not specifically approved by the FDA.

These off label uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances.

Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine.

Regulatory authorities do, however, restrict communications by biopharmaceutical companies concerning off label use.

If we are found to have impermissibly promoted any of our product candidates, we may become subject to significant liability and government fines.

The FDA and other agencies actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off label uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions.

The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off label promotion.

The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.

In the United States, engaging in the impermissible promotion of our products, following approval, for off label uses can also subject us to false claims and other litigation under federal and state statutes.

These include fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and conduct our business.

These restrictions could include corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and suspension and debarment from government contracts and refusal of orders under existing government contracts.

These False Claims Act lawsuits against manufacturers of drugs and biologics have increased significantly in volume and breadth.

In addition, False Claims Act lawsuits may expose manufacturers to follow-on claims by private payers based on fraudulent marketing practices.

This growth in litigation has increased the risk that a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs.

If we do not lawfully promote our approved products, if any, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

In the United States, the promotion of biopharmaceutical products is subject to additional FDA requirements and restrictions on promotional statements.

If after one or more of our product candidates obtains marketing approval the FDA determines that our

promotional activities violate its regulations and policies pertaining to product promotion, it could request that we modify our promotional materials or subject us to regulatory or other enforcement actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market, requests for recalls, payment of civil fines, disgorgement of

money, imposition of operating restrictions, injunctions or criminal prosecution, and other enforcement actions.

Similarly, industry codes in foreign jurisdictions may prohibit companies from engaging in certain promotional activities and regulatory agencies in various countries may enforce violations of such codes with civil penalties.

If we become subject to regulatory and enforcement actions our business, financial condition, results of operations, stock price and prospects will be materially harmed.

Even if our product candidates receive regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense and limit how we manufacture and market our products.

Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing requirements of and review by the FDA and comparable foreign regulatory authorities, including requirements related to the manufacturing processes, post approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, marketing, and promotional activities for such product.

These requirements further include submissions of safety and other postmarketing information, including manufacturing deviations and reports, registration and listing requirements, the payment of annual fees, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing, quality control, quality assurance, and corresponding maintenance of records and documents, and good clinical practices, or GCPs, for any clinical trials that we conduct post approval.

The FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product even after approval.

If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may withdraw approval, issue public safety alerts, require labeling changes or establishment of a REMS or similar strategy, impose significant restrictions on a products indicated uses or marketing, or impose ongoing requirements for potentially costly post approval studies or postmarket surveillance.

● contain requirements for costly post-market testing and surveillance, or other requirements, including the submission of a

risk evaluation and mitigation strategy, or REMS, to monitor the safety or efficacy of the products.

We have not previously submitted a BLA to

the FDA, or a similar marketing application to comparable foreign regulatory authorities, for any product candidate, and we can

provide no assurance that we will ultimately be successful in obtaining regulatory approval for claims that are necessary or desirable

for successful marketing, or at all.

The regulatory approval processes of the FDA and comparable

foreign regulatory authorities are lengthy, time consuming and inherently unpredictable.

If we are not able to obtain, or experience

delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates as expected, and

our ability to generate revenue may be materially impaired.

The time required to obtain approval

by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the

commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory

In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval

may change during the course of a product candidate’s clinical development and may vary among jurisdictions and there

may be varying interpretations of data obtained from preclinical studies or clinical trials, any of which may cause delays or

limitations in the approval or a decision not to approve an application.

These regulatory requirements may require us to

amend our clinical trial protocols, conduct additional preclinical studies or clinical trials that may require regulatory or

IRB approval, or otherwise cause delays in the approval or rejection of an application.

Any delay in obtaining or failure to

obtain required approvals could materially adversely affect our ability to generate revenue from the particular product

candidate, which may materially harm our business, financial condition, results of operations, stock price and prospects.

If we experience delays in obtaining approval,

if we fail to obtain approval of a product candidate or if the label for a product candidate does not include the labeling claims

necessary or desirable for the successful commercialization of that product candidate, the commercial prospects for such product

candidate may be harmed and our ability to generate revenues from that product candidate may be materially impaired.

The FDA or a comparable foreign regulatory authority may

determine that our product candidates have undesirable side effects that could delay or prevent their regulatory approval or commercialization.

To date, the most commonly reported adverse

events observed for RP1 are local injection site reactions and systemic constitutional symptoms, such as fatigue, fevers and chills.

However, there can be no assurance that additional undesirable side effects or serious adverse events will not be caused by or

associated with RP1 or our other product candidates as they continue through or enter clinical development.

Serious adverse events

or undesirable side effects caused by our product candidates could cause us, IRBs, and other reviewing entities or regulatory

authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of

regulatory approval by the FDA or comparable foreign regulatory authorities.

For example, if concerns are raised regarding the

safety of a new therapeutic as a result of undesirable side effects identified during clinical or preclinical testing, the FDA

or comparable foreign regulatory authority may order us to cease further development, decline to approve the product candidate

or issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve

the product candidate.

The FDA or comparable foreign regulatory authorities, or IRBs and other reviewing entities, may also require,

or we may voluntarily develop, strategies for managing adverse events during clinical development, which could include restrictions

on our enrollment criteria, the use of stopping criteria, adjustments to a study’s design, or the monitoring of safety data

by a data monitoring committee, among other strategies.

The FDA or comparable foreign regulatory authority requests for additional

data or information could also result in substantial delays in the approval of our product candidates.

Undesirable side effects caused by any of

our product candidates could also result in denial of regulatory approval by the FDA or comparable foreign regulatory authorities

for any or all targeted indications or the inclusion of unfavorable information in our product labeling, such as limitations on

the indicated uses for which the products may be marketed or distributed, a label with significant safety warnings, including boxed

warnings, contraindications, and precautions, a label without statements necessary or desirable for successful commercialization,

or may result in requirements for costly post-marketing testing and surveillance, or other requirements, including REMS, to monitor

the safety or efficacy of the products, and in turn prevent us from commercializing and generating revenues from the sale of our

product candidates.

Undesirable side effects may limit the potential market for any approved products or could result in the discontinuation

of the sales and marketing of the product, or withdrawal of product approvals.

Later discovered undesirable side effects may further

result in the imposition of a REMS, label revisions, post approval study requirements, or other testing and surveillance.

If any of our product candidates is associated

with serious adverse events or undesirable side effects or have properties that are unexpected, we may need to abandon development

or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other

characteristics are less prevalent, less severe or more acceptable from a risk/benefit perspective.

The therapeutic-related side

effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product

liability claims.

Any of these occurrences may materially harm our business, financial condition, results of operations, stock

price and prospects.

Changes in product candidate manufacturing or formulation

may result in additional costs or delay.

As product candidates are developed through

preclinical studies to later stage clinical trials towards approval and commercialization, it is common that various aspects of

the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes

Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical

trials or other future clinical trials conducted with the altered materials.

Such changes may also require additional testing,

or notification to, or approval by the FDA or a comparable foreign regulatory authority.

This could delay completion of clinical

trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase

clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate

Regulatory approval by the FDA or comparable foreign regulatory

authorities is limited to those specific indications and conditions for which approval has been granted, and we may be subject

to substantial fines, criminal penalties, injunctions, or other enforcement actions if we are determined to be promoting the use

of our products for unapproved or “off label”

uses, resulting in damage to our reputation and business.

We must comply with requirements concerning

advertising and promotion for any product candidates for which we obtain marketing approval.

Promotional communications with respect

to therapeutics are subject to a variety of legal and regulatory restrictions and continuing review by the FDA, Department of Justice,

Department of Health and Human Services’

Office of Inspector General, state attorneys general, members of Congress, and the

When the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory

approval is limited to those specific uses and indications for which a product is approved.

If we are not able to obtain FDA approval

for desired uses or indications for our product candidates, we may not market or promote them for those indications and uses, referred

to as off label uses, and our business, financial condition, results of operations, stock price and prospects may be materially

We also must sufficiently substantiate any claims that we make for our products, including claims comparing our products

to other companies’

products, and must abide by the FDA’s strict requirements regarding the content of promotion and

While physicians may choose to prescribe

products for uses that are not described in the product’s labeling and for uses that differ from those tested in clinical

trials and approved by the regulatory authorities, we are prohibited from marketing and promoting the products for indications

and uses that are not specifically approved by the FDA.

These off label uses are common across medical specialties and may constitute

an appropriate treatment for some patients in varied circumstances.

Regulatory authorities in the United States generally do not

restrict or regulate the behavior of physicians in their choice of treatment within the practice of medicine.

Regulatory authorities

do, however, restrict communications by biopharmaceutical companies concerning off label use.

If we are found to have impermissibly promoted

any of our product candidates, we may become subject to significant liability and government fines.

The FDA and other agencies

actively enforce the laws and regulations regarding product promotion, particularly those prohibiting the promotion of off label

uses, and a company that is found to have improperly promoted a product may be subject to significant sanctions.

The federal government

has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from

engaging in off label promotion.

The FDA has also requested that companies enter into consent decrees or permanent injunctions

under which specified promotional conduct is changed or curtailed.

In the United States, engaging in the impermissible

promotion of our products, following approval, for off label uses can also subject us to false claims and other litigation under

federal and state statutes.

These include fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties

and fines and agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic

products and conduct our business.

These restrictions could include corporate integrity agreements, suspension or exclusion from

participation in federal and state healthcare programs, and suspension and debarment from government contracts and refusal of orders

under existing government contracts.

These False Claims Act lawsuits against manufacturers of drugs and biologics have increased

significantly in volume and breadth.

In addition, False Claims Act lawsuits may expose manufacturers to follow-on claims by private

payers based on fraudulent marketing practices.

This growth in litigation has increased the risk that a biopharmaceutical company

will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to

comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state

healthcare programs.

If we do not lawfully promote our approved products, if any, we may become subject to such litigation and,

if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial

condition, results of operations, stock price and prospects.

In the United States, the promotion of biopharmaceutical

products is subject to additional FDA requirements and restrictions on promotional statements.

If after one or more of our product

candidates obtains marketing approval the FDA determines that our promotional activities violate its regulations and policies pertaining

to product promotion, it could request that we modify our promotional materials or subject us to regulatory or other enforcement

actions, including issuance of warning letters or untitled letters, suspension or withdrawal of an approved product from the market,

requests for recalls, payment of civil fines, disgorgement of money, imposition of operating restrictions, injunctions or criminal

prosecution, and other enforcement actions.

Similarly, industry codes in foreign jurisdictions may prohibit companies from engaging

in certain promotional activities and regulatory agencies in various countries may enforce violations of such codes with civil

If we become subject to regulatory and enforcement actions our business, financial condition, results of operations,

stock price and prospects will be materially harmed.

Even if our product candidates receive regulatory approval,

we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense and

limit how we manufacture and market our products.

Any product candidate for which we obtain

marketing approval will be subject to extensive and ongoing requirements of and review by the FDA and comparable foreign regulatory

authorities, including requirements related to the manufacturing processes, post approval clinical data, labeling, packaging, distribution,

adverse event reporting, shortage reporting, risk management plans, supply chain security, storage, recordkeeping, export, import,

advertising, marketing, and promotional activities for such product.

These requirements further include submissions of safety and

other post-marketing information, including manufacturing deviations and reports, registration and listing requirements, the payment

of annual fees, continued compliance with current Good Manufacturing Practice, or cGMP, requirements relating to manufacturing,

quality control, quality assurance, and corresponding maintenance of records and documents, and good clinical practices, or GCPs,

for any clinical trials that we conduct post approval.

The FDA and comparable foreign regulatory

authorities will continue to closely monitor the safety profile of any product even after approval.

If the FDA or comparable foreign

regulatory authorities become aware of new safety information after approval of any of our product candidates, they may withdraw

approval, issue public safety alerts, require labeling changes or establishment of a REMS or similar strategy, impose significant

restrictions on a product’s indicated uses or marketing, or impose ongoing requirements for potentially costly post approval

studies or post-market surveillance.

Any such restrictions could limit sales of the product.

We and any of our suppliers or collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs and other FDA regulatory requirements.

Application holders must further notify the FDA, and depending on the nature of the change, obtain FDA preapproval for product and manufacturing changes.

In addition, later discovery of previously unknown adverse events or that the product is less effective than previously thought or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements both before and after approval, may yield various negative results, including:

We and any of our suppliers or collaborators,

including our contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance

with cGMPs and other FDA regulatory requirements.

Application holders must further notify the FDA, and depending on the nature

of the change, obtain FDA preapproval for product and manufacturing changes.

In addition, later discovery of previously

unknown adverse events or that the product is less effective than previously thought or other problems with our products, manufacturers

or manufacturing processes, or failure to comply with regulatory requirements both before and after approval, may yield various

negative results, including:

● restrictions on manufacturing, distribution, or marketing of such products;

· restrictions on the labeling, including required additional warnings, such as black boxed warnings, contraindications, precautions, and restrictions on the approved indication or use;

● restrictions on the labeling, including required additional warnings, such as black boxed warnings, contraindications, precautions,

and restrictions on the approved indication or use;

● modifications to promotional pieces;

● issuance of corrective information;

· requirements to conduct postmarketing studies or other clinical trials;

● requirements to conduct post-marketing studies or other clinical trials;

● clinical holds or termination of clinical trials;

6 unchanged sentences

● suspension of marketing or withdrawal of the products from the market;

· regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about the product candidate;

● regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing

warnings or other safety information about the product candidate;

● refusal to approve pending applications or supplements to approved applications that we submit;

4 unchanged sentences

● product seizure or detention;

· FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements;

● FDA debarment, suspension and debarment from government contracts, and refusal of orders under existing government contracts,

exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements;

● injunctions or the imposition of civil or criminal penalties, including imprisonment.

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, or could substantially increase the costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues from its marketing and sale.

Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our business, financial condition, results of operations, stock price and prospects.

The FDAs policies or those of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, limit the marketability of our product candidates, or impose additional regulatory obligations on us.

Any of these events could prevent us from

achieving or maintaining market acceptance of the particular product candidate, if approved, or could substantially increase the

costs and expenses of commercializing such product, which in turn could delay or prevent us from generating significant revenues

from its marketing and sale.

Any of these events could further have other material and adverse effects on our operations and business

and could adversely impact our business, financial condition, results of operations, stock price and prospects.

The FDA’s policies or those of comparable

foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay

regulatory approval of our product candidates, limit the marketability of our product candidates, or impose additional regulatory

obligations on us.

Changes in medical practice and standard of care may also impact the marketability of our product candidates.

If we are slow or unable to adapt to changes in existing requirements, standards of care, or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and be subject to regulatory enforcement action.

Should any of the above actions take place, we could be prevented from or significantly delayed in achieving profitability.

Further, the cost of compliance with post approval regulations may have a negative effect on our operations and business and could adversely impact our business, financial condition, results of operations, stock price and prospects.

Obtaining and maintaining marketing approval for our product candidates in one jurisdiction would not mean that we will be successful in obtaining marketing approval of that product candidate in other jurisdictions, which could prevent us from marketing our products internationally.

Obtaining and maintaining marketing approval of our product candidates in one jurisdiction would not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others.

For example, even if the FDA grants marketing approval of a product candidate, comparable foreign regulatory authorities must also approve the manufacturing, marketing and promotion of the product candidate in those countries.

Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and, in some cases, greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.

In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction.

In some cases, the price that we intend to charge for our products is also subject to approval.

Additionally, the outcome of the United Kingdoms impending withdrawal from the European Union, commonly referred to as Brexit, remains uncertain.

Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, the withdrawal of the United Kingdom from the European Union could materially impact the regulatory regime with respect to the approval of our product candidates in the United Kingdom or the European Union.

Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions.

Obtaining foreign marketing approvals and compliance with foreign regulatory requirements, including compliance with Brexit, could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries.

If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

If we obtain approval for any product candidate and ultimately commercialize that product in foreign markets, we would be subject to additional risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries.

If we are slow or unable to adapt to changes

in existing requirements, standards of care, or the adoption of new requirements or policies, or if we are not able to maintain

regulatory compliance, we may lose any marketing approval that we may have obtained and be subject to regulatory enforcement action.

Should any of the above actions take place,

we could be prevented from or significantly delayed in achieving profitability.

Further, the cost of compliance with post approval

regulations may have a negative effect on our operations and business and could adversely impact our business, financial condition,

results of operations, stock price and prospects.

Obtaining and maintaining marketing approval for our product

candidates in one jurisdiction would not mean that we will be successful in obtaining marketing approval of that product candidate

in other jurisdictions, which could prevent us from marketing our products internationally.

Obtaining and maintaining marketing

approval of our product candidates in one jurisdiction would not guarantee that we will be able to obtain or maintain

marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction

may have a negative effect on the marketing approval process in others.

For example, even if the FDA grants marketing

approval of a product candidate, comparable foreign regulatory authorities must also approve the manufacturing, marketing and

promotion of the product candidate in those countries.

Approval procedures vary among jurisdictions and can involve

requirements and administrative review periods different from and, in some cases, greater than, those in the United States,

including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be

accepted by regulatory authorities in other jurisdictions.

In many jurisdictions outside the United States, a product

candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction.

In some cases, the

price that we intend to charge for our products is also subject to approval.

Additionally, the outcome of the United

Kingdom’s impending withdrawal from the European Union, commonly referred to as Brexit, remains uncertain.

significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and

regulations, the withdrawal of the United Kingdom from the European Union could materially impact the regulatory regime with

respect to the approval of our product candidates in the United Kingdom or the European Union.

Regulatory authorities in jurisdictions

outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing

in those jurisdictions.

Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result

in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries.

If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our

target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

we obtain approval for any product candidate and ultimately commercialize that product in foreign markets, we would be subject

to additional risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting

and legal requirements and the reduced protection of intellectual property rights in some foreign countries.

Risks related to commercialization

If we are unable to successfully commercialize any product candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially harmed.

If we are successful in obtaining marketing approval from applicable regulatory authorities for RP1 or any of our other product candidates, our ability to generate revenues from our product candidates will depend on our success in:

If we are unable to successfully commercialize any product

candidate for which we receive regulatory approval, or experience significant delays in doing so, our business will be materially

If we are successful in obtaining marketing

approval from applicable regulatory authorities for RP1 or any of our other product candidates, our ability to generate revenues

from our product candidates will depend on our success in:

● launching commercial sales of our product candidates, whether alone or in collaboration with others;

· receiving an approved label with claims that are necessary or desirable for successful marketing, and that does not contain safety or other limitations that would impede our ability to market the product candidates;

● receiving an approved label with claims that are necessary or desirable for successful marketing, and that does not contain

safety or other limitations that would impede our ability to market the product candidates;

● creating market demand for our product candidates through marketing, sales and promotion activities;

· hiring, training, and deploying a sales force or contracting with third parties to commercialize product candidates in the United States;

· manufacturing product candidates in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter;

· establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms;

· creating partnerships with, or offering licenses to, third parties to promote and sell product candidates in foreign markets where we receive marketing approval;

● hiring, training, and deploying a sales force or contracting with third parties to commercialize product candidates in the

United States;

● manufacturing product candidates in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch

and thereafter;

● establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially

reasonable terms;

● creating partnerships with, or offering licenses to, third parties to promote and sell product candidates in foreign markets

where we receive marketing approval;

● maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;

3 unchanged sentences

● maintaining a continued acceptable safety profile of our product candidates following launch.

To the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects will be materially harmed.

We face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us.

If their product candidates are shown to be safer or more effective than ours, our commercial opportunity may be reduced or eliminated.

The development and commercialization of cancer immunotherapy products is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary rights.

We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major biopharmaceutical companies, specialty biopharmaceutical companies, and biotechnology companies worldwide.

There are a number of large biopharmaceutical and biotechnology companies that currently market and sell products or are pursuing

the development of products for the treatment of solid tumors, including oncolytic immunotherapy and cancer vaccine approaches.

Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.

While our product candidates are intended to be used in combination with other drugs with different mechanisms of action, if and when marketed they will still compete with a number of drugs that are currently marketed or in development that also target cancer.

To compete effectively with these drugs, our product candidates will need to demonstrate advantages in clinical efficacy and safety compared to these competitors when used alone or in combination with other drugs.

Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are easier to administer or are less expensive alone or in combination with other therapies than any products that we may develop alone or in combination with other therapies.

Our competitors also may obtain FDA or comparable foreign regulatory authorities approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

In addition, our ability to compete may be affected in many cases by insurers or other third party payors coverage decisions.

Many of the companies with which we are competing or may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do.

Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors.

Early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and

established companies.

These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs.

If we are unable to successfully compete with these companies our business, financial condition, results of operations, stock price and prospects may be materially harmed.

If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market and sell our product candidates, if they are approved, the revenues that we generate may be limited and we may never become profitable.

We currently do not have a commercial infrastructure for the marketing, sale, and distribution of our cancer immunotherapies.

If and when our product candidates receive marketing approval, we intend to commercialize our product candidates on our own in the United States and potentially with pharmaceutical or biotechnology partners in other geographies.

In order to commercialize our products, we must build our marketing, sales, and distribution capabilities or make arrangements with third parties to perform these services.

To the extent we are not able to do any

of the foregoing, our business, financial condition, results of operations, stock price and prospects will be materially harmed.

We face significant competition from other biopharmaceutical

and biotechnology companies, academic institutions, government agencies, and other research organizations, which may result in

others discovering, developing or commercializing products more quickly or marketing them more successfully than us.

product candidates are shown to be safer or more effective than ours, our commercial opportunity may be reduced or eliminated.

The development and commercialization of

cancer immunotherapy products is characterized by rapidly advancing technologies, intense competition and a strong emphasis on

proprietary rights.

We face competition with respect to our current product candidates, and will face competition with respect

to any product candidates that we may seek to develop or commercialize in the future, from major biopharmaceutical companies, specialty

biopharmaceutical companies, and biotechnology companies worldwide.

There are a number of large biopharmaceutical and biotechnology

companies that currently market and sell products or are pursuing the development of products for the treatment of solid tumors,

including oncolytic immunotherapy and cancer vaccine approaches.

Potential competitors also include academic institutions, government

agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative

arrangements for research, development, manufacturing, and commercialization.

While our product candidates are intended

to be used in combination with other drugs with different mechanisms of action, if and when marketed they will still compete with

a number of drugs that are currently marketed or in development that also target cancer.

To compete effectively with these drugs,

our product candidates will need to demonstrate advantages in clinical efficacy and safety compared to these competitors when used

alone or in combination with other drugs.

Our commercial opportunities could be reduced

or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side

effects, are easier to administer or are less expensive alone or in combination with other therapies than any products that we

may develop alone or in combination with other therapies.

Our competitors also may obtain FDA or comparable foreign regulatory

authority approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors

establishing a strong market position before we are able to enter the market.

In addition, our ability to compete may be affected

in many cases by insurers or other third-party payors coverage decisions.

Many of the companies with which we are

competing or may compete in the future have significantly greater financial resources and expertise in research and development,

manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products

Mergers and acquisitions in the biopharmaceutical and biotechnology industries may result in even more resources being

concentrated among a smaller number of our competitors.

Early stage companies may also prove to be significant competitors, particularly

through collaborative arrangements with large and established companies.

These third parties compete with us in recruiting and

retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical

trials, as well as in developing or acquiring technologies complementary to, or necessary for, our programs.

If we are unable to

successfully compete with these companies our business, financial condition, results of operations, stock price and prospects may

be materially harmed.

If we are unable to establish effective marketing, sales

and distribution capabilities or enter into agreements with third parties to market and sell our product candidates, if they are

approved, the revenues that we generate may be limited and we may never become profitable.

We currently do not have a commercial infrastructure

for the marketing, sale, and distribution of our product candidates.

If and when our product candidates receive marketing approval,

we intend to commercialize our product candidates on our own in the United States and potentially with pharmaceutical or biotechnology

partners in other geographies.

In order to commercialize our products, we must build our marketing, sales, and distribution capabilities

or make arrangements with third parties to perform these services.

We may not be successful in doing so.

Should we decide to move forward in developing our own marketing capabilities, we may incur expenses prior to product launch or even approval in order to recruit a sales force and develop a marketing and sales infrastructure.

If a commercial launch is delayed as a result of the FDA or comparable foreign regulatory authority requirements or other reasons, we would incur these expenses prior to being able to realize any revenue from sales of our product candidates.

Even if we are able to effectively hire a sales force and develop a marketing and sales infrastructure, our sales force and marketing teams may not be successful in commercializing our product candidates.

Should we decide to move

forward in developing our own marketing capabilities, we may incur expenses prior to product launch or even approval in order to

recruit a sales force and develop a marketing and sales infrastructure.

If a commercial launch is delayed as a result of FDA or

comparable foreign regulatory authority requirements or other reasons, we would incur these expenses prior to being able to realize

any revenue from sales of our product candidates.

Even if we are able to effectively hire a sales force and develop a marketing

and sales infrastructure, our sales force and marketing teams may not be successful in commercializing our product candidates.

This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.

We may also or alternatively decide to collaborate with third party marketing and sales organizations to commercialize any approved product candidates in the United States, in which event, our ability to generate product revenues may be limited.

To the extent we rely on third parties to commercialize any products for which we obtain regulatory approval, we may receive less revenues than if we commercialized these products ourselves, which could materially harm our prospects.

In addition, we would have less control over the sales efforts of any other third parties involved in our commercialization efforts, and could be held liable if they failed to comply with applicable legal or regulatory requirements.

We have no prior experience in the marketing, sale, and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a commercial infrastructure.

The establishment and development of commercial capabilities, including compliance plans, to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability.

We will have to compete with other biopharmaceutical and biotechnology companies, including oncology-focused companies, to recruit, hire, train, manage, and retain marketing and sales personnel, which is expensive and time consuming and could delay any product launch.

Developing our sales capabilities may also divert resources and management attention away from product development.

In the event we are unable to develop a marketing and sales infrastructure, we may not be able to commercialize our product candidates in the United States or elsewhere, which could limit our ability to generate product revenues and materially harm our

business, financial condition, results of operations, stock price and prospects.

We may also or alternatively decide to

collaborate with third-party marketing and sales organizations to commercialize any approved product candidates in the United

States, in which event, our ability to generate product revenues may be limited.

To the extent we rely on third parties to

commercialize any products for which we obtain regulatory approval, we may receive less revenues than if we commercialized

these products ourselves, which could materially harm our prospects.

In addition, we would have less control over the sales

efforts of any other third parties involved in our commercialization efforts, and could be held liable if they failed to

comply with applicable legal or regulatory requirements.

We have no prior experience in the marketing,

sale, and distribution of biopharmaceutical products, and there are significant risks involved in building and managing a commercial

infrastructure.

The establishment and development of commercial capabilities, including compliance plans, to market any products

we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully

develop this capability.

We will have to compete with other biopharmaceutical and biotechnology companies, including oncology-focused

companies, to recruit, hire, train, manage, and retain marketing and sales personnel, which is expensive and time consuming and

could delay any product launch.

Developing our sales capabilities may also divert resources and management attention away from

product development.

In the event we are unable to develop a

marketing and sales infrastructure, we may not be able to commercialize our product candidates in the United States or elsewhere,

which could limit our ability to generate product revenues and materially harm our business, financial condition, results of operations,

stock price and prospects.

Factors that may inhibit our efforts to commercialize our product candidates include:

● the inability to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel;

· the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our product candidates;

● the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our

product candidates;

● our inability to effectively oversee a geographically dispersed sales and marketing team;

· the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions;

● the costs associated with training sales and marketing personnel on legal and regulatory compliance matters and monitoring

their actions;

● an inability to secure adequate coverage and reimbursement by government and private health plans;

● the clinical indications for which the products are approved and the claims that we may make for the products;

· limitations or warnings, including distribution or use restrictions, contained in the products approved labeling;

· any distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree as part of a mandatory REMS or voluntary risk management plan;

● limitations or warnings, including distribution or use restrictions, contained in the products’

approved labeling;

● any distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities or to which we agree

as part of a mandatory REMS or voluntary risk management plan;

● liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements;

· the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;

· unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract sales organization.

Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.

We have concentrated all of our research and development efforts on product candidates based on our Immulytic platform, and our future success depends on the successful development of this therapeutic approach.

There can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be solved.

Should we encounter development problems, including unfavorable preclinical or clinical trial results, the FDA and foreign regulatory authorities may refuse to approve our product candidates, or may require additional information, tests, or trials, which could significantly delay product development and significantly increase our development costs.

Moreover, even if we are able to provide the requested information or trials to the FDA, there would be no guarantee that the FDA would accept them or approve our product candidates.

We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process, or developing or qualifying and validating product release assays, other testing and manufacturing methods, and our equipment and facilities in a timely manner, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.

In addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products.

● the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative

to companies with more extensive product lines;

● unforeseen costs and expenses associated with creating an independent sales and marketing organization or engaging a contract

sales organization.

Our product candidates are based on a novel approach to

the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.

We have concentrated all of our

research and development efforts on product candidates based on our Immulytic platform, and our future success depends on the

successful development of this therapeutic approach.

There can be no assurance that any development problems we experience in

the future will not cause significant delays or unanticipated costs, or that such development problems can be solved.

we encounter development problems, including unfavorable preclinical or clinical trial results, the FDA and foreign

regulatory authorities may refuse to approve our product candidates, or may require additional information, tests, or trials,

which could significantly delay product development and significantly increase our development costs.

Moreover, even if we

are able to provide the requested information or trials to the FDA, there would be no guarantee that the FDA would accept

them or approve our product candidates.

We may also experience delays in developing a sustainable, reproducible and scalable

manufacturing process, or developing or qualifying and validating product release assays, other testing and manufacturing

methods, and our equipment and facilities in a timely manner, which may prevent us from completing our clinical trials or

commercializing our product candidates on a timely or profitable basis, if at all.

In addition, the clinical trial requirements

of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to determine the safety and efficacy

of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential

The FDA and comparable foreign regulatory authorities have limited experience with the approval of oncolytic immunotherapies.

Only one oncolytic immunotherapy, TVec, has received FDA approval to date.

Any product candidates that are approved may be subject to extensive post-approval regulatory requirements, including requirements pertaining to manufacturing, distribution, and promotion.

Only one oncolytic immunotherapy, T-Vec, has received FDA approval to date.

Any product candidates that are approved may be subject

to extensive post approval regulatory requirements, including requirements pertaining to manufacturing, distribution, and promotion.

We may need to devote significant time and resources to compliance with these requirements.

If our product candidates do not achieve broad market acceptance, the revenues that we generate from their sales may be limited, and we may never become profitable.

We have never commercialized a product candidate for any indication.

Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third party payors, and others in the medical community.

If any product candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability.

Market acceptance of our product candidates by the medical community, patients, and third party payors will depend on a number of factors, some of which are

beyond our control.

For example, physicians are often reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially more effective or safer treatments enter the market.

Efforts to educate the medical community and third party payors on the benefits of our product candidates may require significant resources and may not be successful.

If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability.

The degree of market acceptance of any of our product candidates will depend on a number of factors, including:

If our product candidates do not achieve broad market

acceptance, the revenues that we generate from their sales may be limited, and we may never become profitable.

We have never commercialized a product candidate

for any indication.

Even if our product candidates are approved by the appropriate regulatory authorities for marketing and sale,

they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community.

If any product

candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we could be prevented from

or significantly delayed in achieving profitability.

Market acceptance of our product candidates by the medical community, patients,

and third-party payors will depend on a number of factors, some of which are beyond our control.

For example, physicians are often

reluctant to switch their patients and patients may be reluctant to switch from existing therapies even when new and potentially

more effective or safer treatments enter the market.

Efforts to educate the medical community

and third-party payors on the benefits of our product candidates may require significant resources and may not be successful.

any of our product candidates is approved but does not achieve an adequate level of market acceptance, we could be prevented from

or significantly delayed in achieving profitability.

The degree of market acceptance of any of our product candidates will depend

on a number of factors, including:

● the efficacy of our product candidates in combination with marketed checkpoint blockade drugs;

● the commercial success of the checkpoint blockade drugs with which our products are co-administered;

· the prevalence and severity of adverse events associated with our product candidates or those products with which they are co-administered;

● the prevalence and severity of adverse events associated with our product candidates or those products with which they are

co-administered;

● the clinical indications for which the products are approved and the approved claims that we may make for the products;

· limitations or warnings contained in the products FDA-approved labeling or those of comparable foreign regulatory authorities, including potential limitations or warnings for our product candidates that may be more restrictive than other competitive products;

· changes in the standard of care for the targeted indications for our product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained;

· the relative convenience and ease of administration of our product candidates by direct injection into tumors, a less common method for the administration of oncology therapies than systemic administration, which may result in slower adoption of our therapies;

● limitations or warnings contained in the product’s FDA-approved labeling or those of comparable foreign regulatory authorities,

including potential limitations or warnings for our product candidates that may be more restrictive than other competitive products;

● changes in the standard of care for the targeted indications for our product candidates, which could reduce the marketing impact

of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained;

● the relative convenience and ease of administration of our product candidates by direct injection into tumors, a less common

method for the administration of oncology therapies than systemic administration, which may result in slower adoption of our therapies;

● the relative convenience and ease of administration of any products with which our product candidates are co-administered;

● the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;

· the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors, and by government healthcare programs, including Medicare and Medicaid;

● the availability of adequate coverage or reimbursement by third parties, such as insurance companies and other healthcare payors,

and by government healthcare programs, including Medicare and Medicaid;

● the price concessions required by third-party payors to obtain coverage;

● the extent and strength of our marketing and distribution of our product candidates;

· the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved;

· distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our product candidates or to which we agree as part of a REMS or voluntary risk management plan;

● the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that

may later be approved;

● distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our product

candidates or to which we agree as part of a REMS or voluntary risk management plan;

● the timing of market introduction of our product candidates, as well as competitive products;

4 unchanged sentences

● the approval of other new products;

· adverse publicity about our product candidates or any products with which they are co-administered, or favorable publicity about competitive products;

● adverse publicity about our product candidates or any products with which they are co-administered, or favorable publicity

about competitive products;

● potential product liability claims.

The size of the potential market for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates.

The potential market opportunities for our product candidates are difficult to estimate and will depend in large part on the drugs with which our product candidates are co-administered and the success of competing therapies and therapeutic approaches.

In particular, the market opportunity for oncolytic immunotherapies is hard to estimate given that it is an emerging field with only one existing FDA-approved oncolytic immunotherapy, TVec, which has yet to enjoy broad market acceptance.

Our estimates of the

potential market opportunities are predicated on many assumptions, which may include industry knowledge and publications, third party research reports, and other surveys.

Although we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an independent source.

If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities.

Negative developments in the field of immune-oncology could damage public perception of RP1 or any of our other product candidates and negatively affect our business.

The commercial success of our product candidates will depend in part on public acceptance of the use of cancer immunotherapies.

Adverse events in clinical trials of RP1 or our other product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments in the field of immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for RP1 or our other product candidates that we may develop.

These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials.

If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our therapies or those of our competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our clinical trials.

As a result, we may not be able to continue or may be delayed in conducting our development programs.

As our product candidates consist of a modified virus, adverse developments in antiviral vaccines or clinical trials of other oncolytic immunotherapy products based on viruses may result in a disproportionately negative effect for RP1 or our other product candidates as compared to other products in the field of immune-oncology that are not based on viruses.

Future negative developments in the field of immune-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products.

Any increased scrutiny could delay or increase the costs of obtaining marketing approval for RP1 or our other product candidates.

Risks related to our financial position and need for additional capital

We are a clinical stage biopharmaceutical company with a very limited operating history.

We have incurred net losses since our inception and anticipate that we will continue to incur substantial and increasing net losses in the foreseeable future.

The size of the potential market for our product candidates

is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller

than our estimates.

The potential market opportunities for our

product candidates are difficult to estimate and will depend in large part on the drugs with which our product candidates are co-administered

and the success of competing therapies and therapeutic approaches.

In particular, the market opportunity for oncolytic immunotherapies

is hard to estimate given that it is an emerging field with only one existing FDA-approved oncolytic immunotherapy, T-Vec, which

has yet to enjoy broad market acceptance.

Our estimates of the potential market opportunities are predicated on many assumptions,

which may include industry knowledge and publications, third-party research reports, and other surveys.

Although we believe that

our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management,

are inherently uncertain, and their reasonableness has not been assessed by an independent source.

If any of the assumptions proves

to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential market opportunities.

Negative developments in the field of immuno-oncology

could damage public perception of RP1 or any of our other product candidates and negatively affect our business.

The commercial success of our product candidates

will depend in part on public acceptance of the use of cancer immunotherapies.

Adverse events in clinical trials of RP1 or our

other product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any

other negative developments in the field of immuno-oncology that may occur in the future, including in connection with competitor

therapies, could result in a decrease in demand for RP1 or our other product candidates that we may develop.

These events could

also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials.

If public perception

is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our therapies or those of our competitors,

our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects

may be discouraged from enrolling in our clinical trials.

As a result, we may not be able to continue or may be delayed in conducting

our development programs.

As our product candidates consist of a modified

virus, adverse developments in antiviral vaccines or clinical trials of other oncolytic immunotherapy products based on viruses

may result in a disproportionately negative effect for RP1 or our other product candidates as compared to other products in the

field of immuno-oncology that are not based on viruses.

Future negative developments in the field of immuno-oncology or the biopharmaceutical

industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in

the testing or approvals of our products.

Any increased scrutiny could delay or increase the costs of obtaining marketing approval

for RP1 or our other product candidates.

Risks related to our financial position and need for additional

We are a clinical stage biopharmaceutical company with

a very limited operating history.

We have incurred net losses since our inception and anticipate that we will continue to incur

substantial and increasing net losses in the foreseeable future.

We may never achieve or sustain profitability.

We are a clinical stage biopharmaceutical company with a limited operating history, and we are early in our development efforts.

We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operations.

Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain marketing approval and become commercially viable.

We have financed our operations to date primarily through the sale of equity securities, including the sale of our common stock in our public offerings.

Since our inception, most of our resources have been dedicated to the preclinical and clinical development of our Immulytic platform, RP1 and our other product candidates.

The size of our future net losses will depend, in part, on our future expenses and our ability to generate revenue, if any.

We are not profitable and have incurred losses in each period since our inception.

For the years ended March 31, 2019 and 2018, we reported a net loss of $30.8 million and $19.7 million, respectively.

For the three and nine months ended December 31, 2019, we reported a net loss of $16.2 million and $36.8 million, respectively.

For the three and nine months ended December 31, 2018, we reported a net loss of $7.7 million and $24.2 million, respectively.

At December 31, 2019, we had an accumulated deficit of $96.5 million.

We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we

continue our research and development of, and seek marketing approvals for, RP1 and any additional product candidates we may develop.

Even if we succeed in receiving marketing approval for and commercialize RP1, we will continue to incur substantial research and development and other expenditures to develop and market additional potential products.

We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.

The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.

Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders equity and working capital.

We have never generated any revenue from product sales, and our ability to generate revenue from product sales and become profitable will depend significantly on our success in achieving a number of goals.

We have no products approved for commercial sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from product sales until after we have received marketing approval for the commercial sale of a product candidate, if ever.

Our ability to generate revenue and achieve profitability depends significantly on our success in achieving a number of goals, including:

We are a clinical stage biopharmaceutical

company with a limited operating history, and we are early in our development efforts.

We have no products approved for commercial

sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development

and other expenses related to our ongoing operations.

Investment in biopharmaceutical product development is highly speculative

because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail

to demonstrate adequate efficacy or an acceptable safety profile, gain marketing approval and become commercially viable.

financed our operations to date primarily through the sale of equity securities, including the sale of our common stock in our

public offerings.

Since our inception, most of our resources have been dedicated to the preclinical and clinical development of

our Immulytic platform, RP1 and our other product candidates.

The size of our future net losses will depend, in part, on our future

expenses and our ability to generate revenue, if any.

We are not profitable and have incurred

losses in each period since our inception.

For the three months ended June 30, 2020 we reported a net loss of $17.5 million.

At June 30, 2020, we had an accumulated deficit of $129.8 million.

We expect to continue to incur significant losses for the

foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek marketing approvals

for, RP1, our other product candidates and any additional product candidates we may develop.

Even if we succeed in receiving marketing

approval for and commercialize RP1, we will continue to incur substantial research and development and other expenditures to develop

and market additional potential products.

We may encounter unforeseen expenses, difficulties, complications, delays and other unknown

factors that may adversely affect our business.

The size of our future net losses will depend, in part, on the rate of future growth

of our expenses and our ability to generate revenue.

Our prior losses and expected future losses have had and will continue to

have an adverse effect on our stockholders’

equity and working capital.

We have never generated any revenue from product sales,

and our ability to generate revenue from product sales and become profitable will depend significantly on our success in achieving

a number of goals.

We have no products approved for commercial

sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from product sales until

after we have received marketing approval for the commercial sale of a product candidate, if ever.

Our ability to generate revenue

and achieve profitability depends significantly on our success in achieving a number of goals, including:

● completing research regarding, and preclinical and clinical development of, RP1 and our other product candidates;

● obtaining marketing approvals for RP1 and our other product candidates for which we complete clinical trials;

· developing a sustainable and scalable manufacturing process for RP1 and our other product candidates, including establishing and maintaining commercially viable supply and manufacturing relationships with third parties;

· launching and commercializing RP1 and our other product candidates for which we obtain marketing approvals, either directly or with a collaborator or distributor;

● developing a sustainable and scalable manufacturing process for RP1 and our other product candidates, including establishing

and maintaining commercially viable supply and manufacturing relationships with third parties;

● launching and commercializing RP1 and our other product candidates for which we obtain marketing approvals, either directly

or with a collaborator or distributor;

● obtaining market acceptance of RP1 and our other product candidates as viable treatment options;

2 unchanged sentences

● negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;

· obtaining, maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how;

● obtaining, maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets,

and know-how;

● attracting, hiring, and retaining qualified personnel.

Even if our product candidates or any future product candidates that we develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any such product candidate.

Our expenses could increase beyond expectations if we are required by the FDA or comparable foreign regulatory authorities to change our manufacturing processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate.

If we are successful in obtaining regulatory approvals to market RP1 or our other product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain marketing approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory.

If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, the labels for our product candidates contain significant safety warnings, regulatory authorities impose burdensome or restrictive distribution requirements, or the reasonably accepted patient population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.

If we are not able to generate revenue from the sale of any approved products, we could be prevented from or significantly delayed in achieving profitability.

We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development or commercialization efforts.

Our operations have consumed substantial amounts of cash since inception.

At December 31, 2019, our cash and cash equivalents and short-term investments were $180.9 million We expect to continue to spend substantial amounts to continue the

clinical and preclinical development of RP1 and our other product candidates.

Even if our product candidates or any future

product candidates that we develop are approved for commercial sale, we anticipate incurring significant costs associated with

commercializing any such product candidate.

Our expenses could increase beyond expectations if we are required by the FDA or comparable

foreign regulatory authorities to change our manufacturing processes or assays, or to perform clinical, nonclinical, or other types

of studies in addition to those that we currently anticipate.

If we are successful in obtaining regulatory

approvals to market RP1 or our other product candidates, our revenue will be dependent, in part, upon the size of the markets in

the territories for which we gain marketing approval, the accepted price for the product, the ability to get reimbursement at any

price, and whether we own the commercial rights for that territory.

If the number of our addressable patients is not as significant

as we estimate, the indication approved by regulatory authorities is narrower than we expect, the labels for our product candidates

contain significant safety warnings, regulatory authorities impose burdensome or restrictive distribution requirements, or the

reasonably accepted patient population for treatment is narrowed by competition, physician choice or treatment guidelines, we may

not generate significant revenue from sales of such products, even if approved.

If we are not able to generate revenue from the

sale of any approved products, we could be prevented from or significantly delayed in achieving profitability.

We will require substantial additional financing to achieve

our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay,

limit, reduce or terminate our product development or commercialization efforts.

Our operations have consumed substantial

amounts of cash since inception.

At June 30, 2020, our cash and cash equivalents and short-term investments were $261.8 million

We expect to continue to spend substantial amounts to continue the clinical and preclinical development of RP1 and our other product

Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.

If we are able to gain marketing approval of any product candidate, we will

require significant additional amounts of cash in order to launch and commercialize such product.

If we are able

to gain marketing approval of any product candidate, we will require significant additional amounts of cash in order to launch

and commercialize such product.

In addition, other unanticipated costs may arise.

Our future capital requirements depend on many factors, including:

· the scope, progress, results and costs of researching and developing RP1 and our other product candidates, and conducting preclinical studies and clinical trials;

· the timing of, and the costs involved in, obtaining marketing approvals for RP1 and our other product candidates if clinical trials are successful;

Our future capital requirements depend on

many factors, including:

● the scope, progress, results and costs of researching and developing RP1 and our other product candidates, and conducting preclinical

studies and clinical trials;

● the timing of, and the costs involved in, obtaining marketing approvals for RP1 and our other product candidates if clinical

trials are successful;

● the success of any collaborations;

1 unchanged sentence

● the cost and timing of operating our manufacturing facility;

· the cost of manufacturing RP1 and our other product candidates for clinical trials in preparation for marketing approval and commercialization;

● the cost of manufacturing RP1 and our other product candidates for clinical trials in preparation for marketing approval and

commercialization;

● our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;

· the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;

● the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including

litigation costs and the outcome of such litigation;

● the timing, receipt, and amount of sales of, or royalties on, our future products, if any;

● the emergence of competing cancer therapies and other adverse market developments.

We do not have any committed external source of funds or other support for our development efforts.

Until we can generate sufficient product revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements.

Based on our research and development plans, we expect that our existing cash and cash equivalents and short term investments will enable us to fund our planned operating expenses and capital expenditure requirements into the second half of calendar year 2022.

We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.

In addition, because the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of RP1 or our other product candidates.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, our existing stockholders interest will be diluted.

Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we are unable to raise additional funds through equity or debt financings when needed, we may be required to grant rights to develop and market one or more of our product candidates or technologies that we would otherwise prefer to develop and market ourselves.

We do not have any committed external source

of funds or other support for our development efforts.

Until we can generate sufficient product revenue to finance our cash requirements,

which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings,

debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements.

Our ability to obtain debt financing may be limited by covenants we have made under our Loan and Security Agreement with Hercules

Capital, Inc.

(“Hercules”) and our pledge to Hercules of our assets as collateral.

Based on our research and development

plans, we expect that our existing cash and cash equivalents and short-term investments will enable us to fund our planned operating

expenses and capital expenditure requirements to mid-2023.

We have based this estimate on assumptions that may prove to be wrong,

and we could exhaust our available capital resources sooner than we expect.

In addition, because the design and outcome of our

planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully

complete the development and commercialization of RP1 or our other product candidates.

Raising additional capital may cause dilution to our stockholders,

restrict our operations or require us to relinquish rights to our technologies or product candidates.

To the extent that we raise additional capital

through the sale of common stock or securities convertible or exchangeable into common stock, our existing stockholders’

interest will be diluted.

Debt financing, if available, would increase our fixed payment obligations and may involve agreements

that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making

capital expenditures or declaring dividends.

If we are unable to raise additional funds

through equity or debt financings when needed, we may be required to grant rights to develop and market one or more of our product

candidates or technologies that we would otherwise prefer to develop and market ourselves.

Risks related to intellectual property

If we are unable to obtain, maintain and protect our intellectual property rights for our technology and product candidates, or if our intellectual property rights are inadequate, our competitive position could be harmed.

Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our technology, Immulytic platform, RP1 and our other product candidates.

We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with

employees and third parties, all of which offer only limited protection.

We seek to protect our proprietary position by filing and prosecuting patent applications in the United States and abroad related to our technology and product candidates.

The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation.

As a result, the issuance, scope, validity, enforceability and commercial value of our licensed patents and any patents we own in the future are highly uncertain.

The steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside of the United States.

Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue.

If we are unable to obtain, maintain and protect our intellectual

property rights for our technology and product candidates, or if our intellectual property rights are inadequate, our competitive

position could be harmed.

Our commercial success will depend in part

on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries

with respect to our technology, Immulytic platform, RP1 and our other product candidates.

We rely on trade secret, patent,

copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which

offer only limited protection.

We seek to protect our proprietary position by filing and prosecuting patent applications in the

United States and abroad related to our technology and product candidates.

The patent positions of biotechnology and

pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been

the subject of much litigation.

As a result, the issuance, scope, validity, enforceability and commercial value of our licensed

patents and any patents we own in the future are highly uncertain.

The steps we have taken to protect our proprietary rights may

not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights,

both inside and outside of the United States.

Further, the examination process may

require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may

be obtained if these applications issue.

The scope of a patent may also be reinterpreted after issuance.

The rights that may be granted under our future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking.

If we are unable to obtain and maintain patent protection for our technology or for RP1 or our other product candidates, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize products similar or superior to ours, and our ability to successfully commercialize RP1 or our other product candidates and future technologies may be adversely affected.

It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them.

In addition, the patent prosecution process is expensive, time consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner.

Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.

It is also possible that we will fail to identify patentable aspects of our research and development efforts in time to obtain patent protection.

For the core technology in our Immulytic platform and each of our product candidates, we have filed five patent applications under the Patent Cooperation Treaty, or PCT, and four U.S.

The rights that may

be granted under our future issued patents may not provide us with the proprietary protection or competitive advantages we

If we are unable to obtain and maintain patent protection for our technology or for RP1 or our other product

candidates, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and

commercialize products similar or superior to ours, and our ability to successfully commercialize RP1 or our other product

candidates and future technologies may be adversely affected.

It is also possible that we will fail to identify patentable

aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain

patent protection on them.

In addition, the patent prosecution process

is expensive, time consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary

or desirable patent applications at a reasonable cost or in a timely manner.

Although we enter into nondisclosure and confidentiality

agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our

employees, collaborators, and other third parties, any of these parties may breach the agreements and disclose such output before

a patent application is filed, thereby jeopardizing our ability to seek patent protection.

It is also possible that we will fail

to identify patentable aspects of our research and development efforts in time to obtain patent protection.

For the core technology in our Immulytic

platform and each of our product candidates, we have filed six patent applications under the PCT.

Five of these PCT applications

have entered the national phase and are pending in a range of countries, and one is still in the international phase.

patents have been granted.

Other than the foregoing, none of our PCT-derived patent applications or U.S.

provisional applications

Four of these PCT applications have entered the national phase and are pending in a range of countries, and one is still in the international phase.

None of our PCT-derived patent applications or U.S.

provisional applications have been granted by a patent office.

Early stage examination has started only in connection with the European national phase applications.

Any future provisional patent applications are not eligible to become issued patents until, among other things, we file a non-provisional patent application within 12 months of filing of one or more of our related provisional patent applications.

If we do not timely file any non-provisional patent applications, we may lose our priority date with respect to our provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications.

Although we intend to timely file non-provisional patent applications relating to our provisional patent applications, we cannot predict whether any of our future patent applications will result in the issuance of patents that effectively protect our technology or RP1 or our other product candidates, or if any of our future issued patents will effectively prevent others from commercializing competitive products.

Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some cases not at all until they are issued as a patent.

Therefore, we cannot be certain that we were the first to make the inventions claimed in our pending patent applications, or that we were the first to file for patent protection of such inventions.

Our pending applications cannot be enforced against third parties practicing the inventions claimed in such applications unless and until a patent issues from such applications.

Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we license from third parties or own in the future may be challenged in the courts or patent offices in the United States and abroad, including through opposition proceedings, derivation proceedings, inter partes review, interference proceedings or litigation.

Such proceedings may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection for our technology.

Protecting against the unauthorized use of our patented inventions, trademarks and other intellectual property rights is expensive, time consuming, difficult and in some cases may not be possible.

In some cases, it may be difficult or impossible to detect third party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult.

If we are unable to obtain, maintain, and protect our intellectual property our competitive advantage could be harmed, and it could result in a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.

In addition to seeking patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and proprietary information.

To maintain the confidentiality of our trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and other third parties who have access to our

have been granted by a patent office and examination has started only in connection with the European and US national phase applications.

Any future provisional patent applications are not eligible to become issued patents until, among other things, we file a

non-provisional patent application within 12 months of filing of one or more of our related provisional patent applications.

If we do not timely file any non-provisional patent applications, we may lose our priority date with respect to our provisional

patent applications and any patent protection on the inventions disclosed in our provisional patent applications.

Although we intend

to timely file non-provisional patent applications relating to our provisional patent applications, we cannot predict whether any

of our future patent applications will result in the issuance of patents that effectively protect our technology or RP1 or our

other product candidates, or if any of our future issued patents will effectively prevent others from commercializing competitive

Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications

in the United States and other jurisdictions are typically not published until 18 months after filing or in some cases not

at all until they are issued as a patent.

Therefore, we cannot be certain that we were the first to make the inventions claimed

in our pending patent applications, or that we were the first to file for patent protection of such inventions.

Our pending applications cannot be enforced

against third parties practicing the inventions claimed in such applications unless and until a patent issues from such applications.

Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that

we license from third parties or own in the future may be challenged in the courts or patent offices in the United States and abroad,

including through opposition proceedings, derivation proceedings, inter partes review, interference proceedings or litigation.

Such proceedings may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability

of such patents, which could limit our ability to stop others from using or commercializing similar or identical products, or limit

the duration of the patent protection for our technology.

Protecting against the unauthorized use of our patented inventions, trademarks

and other intellectual property rights is expensive, time consuming, difficult and in some cases may not be possible.

In some cases,

it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even

in relation to issued patent claims, and proving any such infringement may be even more difficult.

If we are unable to obtain,

maintain, and protect our intellectual property our competitive advantage could be harmed, and it could result in a material adverse

effect on our business, financial condition, results of operations, stock price and prospects.

If we are unable to protect the confidentiality of our

proprietary information and know-how, the value of our technology and products could be adversely affected.

In addition to seeking patent protection,

we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and proprietary information.

To maintain the confidentiality of our trade secrets and proprietary information, we enter into confidentiality agreements with

our employees, consultants, collaborators and other third parties who have access to our trade secrets.

Our agreements with employees

also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property.

However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply

with their terms.

The assignment of intellectual property rights may not be self-executing or the assignment agreements may be

breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine

the ownership of what we regard as our intellectual property.

In addition, in the event of unauthorized use or disclosure of our

trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly

for our trade secrets or other confidential information.

To the extent that our employees, consultants or contractors use technology

or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights

in related inventions.

Adequate remedies may not exist in the event

of unauthorized use or disclosure of our confidential information including a breach of our confidentiality agreements.

a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the

outcome is unpredictable.

In addition, some courts in and outside of the United States are less willing or unwilling to protect

trade secrets.

Our agreements with employees also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property.

However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms.

The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.

In addition, in the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information.

To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions.

Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information including a breach of our confidentiality agreements.

Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the outcome is unpredictable.

In addition, some courts in and outside of the United States are less willing or unwilling to protect trade secrets.

If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us.

The disclosure of our trade secrets or the independent development of our trade secrets by a competitor or other third party would impair our competitive position and may materially harm our business, financial condition, results of operations, stock price and prospects.

Third parties may in the future initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could harm our business.

Our commercial success depends on our ability and the ability of our current or future collaborators to develop, manufacture, market and sell RP1 and our other product candidates, and to use our related proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties.

The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights.

We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any other future product candidates, including interference proceedings, post-grant review, inter partes review and derivation proceedings before the U.S.

Patent and Trademark Office, or USPTO.

Third parties may assert infringement or other intellectual property claims against us based on existing patents or patents that may be granted in the future.

If we are found to infringe a third partys intellectual property rights, and we are unsuccessful in demonstrating that such intellectual property rights are invalid or unenforceable, we could be required to obtain a license from such third party to continue developing, manufacturing and commercializing RP1 and our other product candidates.

If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third

party, we would have no right to prevent them from using that technology or information to compete with us.

The disclosure of our

trade secrets or the independent development of our trade secrets by a competitor or other third party would impair our competitive

position and may materially harm our business, financial condition, results of operations, stock price and prospects.

Third parties may in the future initiate legal proceedings

alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could harm our

Our commercial success depends on our ability

and the ability of our current or future collaborators to develop, manufacture, market and sell RP1 and our other product candidates,

and to use our related proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property

and proprietary rights of third parties.

The biotechnology and pharmaceutical industries are characterized by extensive litigation

regarding patents and other intellectual property rights.

We may become party to, or threatened with, adversarial proceedings or

litigation regarding intellectual property rights with respect to our current and any other future product candidates, including

interference proceedings, post-grant review, inter partes review and derivation proceedings before the U.S.

Patent and Trademark

Office, or USPTO.

Third parties may assert infringement or other intellectual property claims against us based on existing patents

or patents that may be granted in the future.

If we are found to infringe a third-party’s intellectual property rights, and

we are unsuccessful in demonstrating that such intellectual property rights are invalid or unenforceable, we could be required

to obtain a license from such third-party to continue developing, manufacturing and commercializing RP1 and our other product candidates.

However, we may not be able to obtain any required license on commercially reasonable terms or at all.

Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments.

We also could be forced, including by court order, to cease developing, manufacturing, and commercializing RP1 or our other product candidates.

In addition, in any such proceeding or litigation, we could be found liable for significant monetary damages, including treble damages and attorneys fees, if we are found to have willfully infringed a patent or other intellectual property right.

Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

Any claims by third parties that we have misappropriated their confidential information or trade secrets could have a similar material adverse effect on our business.

In addition, we are developing certain of our product candidates in combination with nivolumab and cemiplimab, which are covered by patents or licenses held by BMS and Regeneron, respectively, to which we do not have a license other than for use in connection with the applicable clinical trial.

We also plan to develop our product candidates in combination with products developed by additional companies that are covered by patents or licenses held by those entities to which we do not have a license.

In the event that a labeling instruction is required in product packaging recommending that combination, we could be accused of, or held liable for, infringement of the third party patents covering the product candidate or product recommended for administration with RP1 or our other product candidates.

In such a case, we could be required to obtain a license from the other company or institution to use the required or desired package labeling, which may not be available on commercially reasonable terms, or at all.

We may not be able to protect our intellectual property and proprietary rights throughout the world.

Filing, prosecuting and defending patents on our technology in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States.

In addition, the laws and practices of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.

Consequently, we may not be able to prevent third parties from practicing our

inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.

Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop and/or manufacture their own products and may export otherwise infringing products to territories where we

have patent protection but where enforcement is not as strong as that in the United States.

These products may compete with our products and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.

The legal systems of certain countries, particularly certain developing countries, do not favor the granting or enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to obtain patent rights or stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally in those countries.

Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us.

We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.

Accordingly, our efforts to protect and enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property we develop or license.

In addition, the laws of certain foreign countries may not protect our rights to the same extent as the laws of the United States, and those foreign laws may also be subject to change.

For example, methods of treatment and manufacturing processes may not be patentable in certain jurisdictions, and the requirements for patentability may differ in certain countries.

Furthermore, biosimilar product manufacturers or other competitors may challenge the scope, validity and enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or proceedings.

Moreover, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties.

Many countries limit the enforceability of patents against government agencies or government contractors.

In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent.

If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be adversely affected.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.

The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payments and other similar provisions during the patent application process and to maintain patents after they are issued.

For example, periodic maintenance fees, renewal fees, annuity fees and various other government fees on issued patents and patent applications often must be paid to the USPTO and foreign patent agencies over the lifetime of our licensed patents or any patents we own in the future.

In certain circumstances, we may rely on future licensing partners to take the necessary action to comply with these requirements with respect to licensed intellectual property.

Although an unintentional lapse can be cured for a period of time by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.

Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, nonpayment of fees and failure to properly legalize and submit formal documents.

If we fail to obtain and maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to RP1 or our other product candidates, which could have a material adverse effect on our business.

Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect RP1 and our other product candidates.

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.

Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain.

Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs.

Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

Even if we were able to

obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies

licensed to us, and it could require us to make substantial licensing and royalty payments.

We also could be forced, including

by court order, to cease developing, manufacturing, and commercializing RP1 or our other product candidates.

In addition, in any

such proceeding or litigation, we could be found liable for significant monetary damages, including treble damages and attorneys’

fees, if we are found to have willfully infringed a patent or other intellectual property right.

Any of the foregoing could have

a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

Any claims by

third parties that we have misappropriated their confidential information or trade secrets could have a similar material adverse

effect on our business.

In addition, we are developing certain of

our product candidates in combination with nivolumab and cemiplimab, which are covered by patents or licenses held by BMS and Regeneron,

respectively, to which we do not have a license other than for use in connection with the applicable clinical trial.

to develop our product candidates in combination with products developed by additional companies that are covered by patents or

licenses held by those entities to which we do not have a license.

In the event that a labeling instruction is required in product

packaging recommending that combination, we could be accused of, or held liable for, infringement of the third-party patents covering

the product candidate or product recommended for administration with RP1 or our other product candidates.

In such a case, we could

be required to obtain a license from the other company or institution to use the required or desired package labeling, which may

not be available on commercially reasonable terms, or at all.

We may not be able to protect our intellectual property

and proprietary rights throughout the world.

Filing, prosecuting and defending patents

on our technology in all countries throughout the world would be prohibitively expensive, and our intellectual property rights

in some countries outside the United States can be less extensive than those in the United States.

In addition, the laws and practices

of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United

Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United

States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.

may use our technologies in jurisdictions where we have not obtained patent protection to develop and/or manufacture their own

products and may export otherwise infringing products to territories where we have patent protection but where enforcement is not

as strong as that in the United States.

These products may compete with our products and our patent claims or other intellectual

property rights may not be effective or sufficient to prevent them from so competing.

Many companies have encountered significant

problems in protecting and defending intellectual property rights in certain foreign jurisdictions.

The legal systems of certain

countries, particularly certain developing countries, do not favor the granting or enforcement of patents, trade secrets and other

intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to obtain

patent rights or stop the infringement of our patents or marketing of competing products in violation of our intellectual property

and proprietary rights generally in those countries.

Proceedings to enforce our intellectual property and proprietary rights in

foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business,

could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and

could provoke third parties to assert claims against us.

We may not prevail in any lawsuits that we initiate, and the damages or

other remedies awarded, if any, may not be commercially meaningful.

Accordingly, our efforts to protect and enforce our intellectual

property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual

property we develop or license.

In addition, the laws of certain foreign

countries may not protect our rights to the same extent as the laws of the United States, and those foreign laws may also be subject

For example, methods of treatment and manufacturing processes may not be patentable in certain jurisdictions, and the

requirements for patentability may differ in certain countries.

Furthermore, biosimilar product manufacturers or other competitors

may challenge the scope, validity and enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation

or proceedings.

Moreover, many countries have compulsory

licensing laws under which a patent owner may be compelled to grant licenses to third parties.

Many countries limit the enforceability

of patents against government agencies or government contractors.

In these countries, the patent owner may have limited remedies,

which could materially diminish the value of such patent.

If we are forced to grant a license to third parties with respect to

any patents relevant to our business, our competitive position may be impaired and our business and results of operations may be

adversely affected.

Obtaining and maintaining patent protection depends on

compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies,

and our patent protection could be reduced or eliminated for noncompliance with these requirements.

The USPTO and various foreign governmental

patent agencies require compliance with a number of procedural, documentary, fee payments and other similar provisions during the

patent application process and to maintain patents after they are issued.

For example, periodic maintenance fees, renewal fees,

annuity fees and various other government fees on issued patents and patent applications often must be paid to the USPTO and foreign

patent agencies over the lifetime of our licensed patents or any patents we own in the future.

In certain circumstances, we may

rely on future licensing partners to take the necessary action to comply with these requirements with respect to licensed intellectual

Although an unintentional lapse can be cured for a period of time by payment of a late fee or by other means in accordance

with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent

application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.

Noncompliance events that could

result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official

actions within prescribed time limits, nonpayment of fees and failure to properly legalize and submit formal documents.

to obtain and maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor

from marketing products that are the same as or similar to RP1 or our other product candidates, which could have a material adverse

effect on our business.

Changes to the patent law in the United States and other

jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect RP1 and our other product

As is the case with other

biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.

Obtaining and

enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly,

time consuming and inherently uncertain.

Changes in either the patent laws or interpretation of the patent laws in the United

States could increase the uncertainties and costs.

Patent reform legislation in the United States and other countries,

including the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law on September 16, 2011, could

increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense

of our issued patents.

The Leahy-Smith Act includes a number of significant changes to U.S.

These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost effective avenues for competitors to challenge the validity of patents.

These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings.

After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to

file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention.

However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations.

These include

provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and

cost-effective avenues for competitors to challenge the validity of patents.

These include allowing third-party submission of

prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO

administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings,

even in applications filed before the Leahy-Smith Act came into effect.

Because these third-party challenges before the USPTO

have a lower evidentiary bar for patent invalidation as compared with the evidentiary standard in a U.S.

Federal Court, it is

possible for a third party to invalidate a patent claim before the USPTO that would not have been invalidated before a

District Court.

Additionally, rights of review and appeal for these USPTO third-party challenges is still a developing area

On March 16 2013, under the Leahy-Smith

Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements

are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether

a third party was the first to invent the claimed invention.

Since patent applications in the United States and many other countries

are confidential for a period of time after a filing, we cannot be certain that we were the first to file any patent application

or first to invent any of the inventions claimed in our patents or patent applications.

Thus, the Leahy-Smith Act and its implementation

could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense

of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations,

stock price and prospects.

Supreme Court has ruled on several

patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the

rights of patent owners in certain situations.

Depending on future actions by the U.S.

Congress, the U.S.

courts, the USPTO and the relevant lawmaking bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful and have a material adverse effect on the success of our business.

Competitors may infringe any future licensed patents or any patent we own in the future or misappropriate or otherwise violate our intellectual property rights.

We may also be required to defend against claims of infringement and our licensed patents and any patents we own in the future may become involved in priority or other intellectual property related disputes.

To counter infringement or unauthorized use, litigation may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the validity and scope of our own intellectual property rights or the proprietary rights of others.

Also, third parties may initiate legal proceedings against us to assert that we are infringing their intellectual property rights or to challenge the validity or scope of our owned or licensed intellectual property rights.

courts, the USPTO and

the relevant lawmaking bodies in other countries, the laws and regulations governing patents could change in unpredictable ways

that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the

We may become involved in lawsuits to protect or enforce

our intellectual property, which could be expensive, time consuming and unsuccessful and have a material adverse effect on the

success of our business.

Competitors may infringe any future licensed

patents or any patent we own in the future or misappropriate or otherwise violate our intellectual property rights.

be required to defend against claims of infringement and our licensed patents and any patents we own in the future may become involved

in priority or other intellectual property related disputes.

To counter infringement or unauthorized use, litigation may be necessary

in the future to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the validity

and scope of our own intellectual property rights or the proprietary rights of others.

Also, third parties may initiate legal proceedings

against us to assert that we are infringing their intellectual property rights or to challenge the validity or scope of our owned

or licensed intellectual property rights.

These proceedings can be expensive and time consuming.

Many of our current and potential competitors have the ability to dedicate substantially greater resources to conduct intellectual property related litigations or proceedings than we can.

Many of our current and potential

competitors have the ability to dedicate substantially greater resources to conduct intellectual property related litigations or

proceedings than we can.

We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately.

Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property.

Litigation and other intellectual property related proceedings could result in substantial costs and diversion of management resources, which could harm our business and financial results.

In addition, in an infringement proceeding, a court may decide that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.

An adverse result in any litigation or other intellectual property related proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation in the United States, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

There could also be public announcements of the results of hearings, motions or other interim proceedings or developments in any such proceedings.

If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock.

Any of the foregoing may have a material adverse effect our business, financial condition, results of operations, stock price and prospects.

We may be subject to claims by third parties asserting that our collaborators, employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.

Many of our employees, including our senior management team, were previously employed at, or consulted for, universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.

Our collaborators employees may currently be or previously have been employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors.

Some of these persons, including each member of our senior management team, executed proprietary rights, nondisclosure and noncompetition agreements, or similar agreements, in connection with such previous employment or consulting agreements, that assigned ownership of intellectual property relating to work performed under such agreements to the contracting third party.

Although we take steps to ensure that our employees do not use, claim as theirs, or misappropriate the intellectual property, proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used, claimed as theirs, misappropriated or disclosed intellectual property, including trade secrets or other proprietary information, of any such individuals current or former employer.

Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual

Litigation and other intellectual property related proceedings could result in substantial costs and diversion of management

resources, which could harm our business and financial results.

In addition, in an infringement proceeding, a court may decide

that a patent owned by or licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the technology

at issue on the grounds that our patents do not cover the technology in question.

An adverse result in any litigation or other

intellectual property related proceeding could put one or more of our patents at risk of being invalidated, held unenforceable

or interpreted narrowly.

Furthermore, because of the substantial

amount of discovery required in connection with intellectual property litigation in the United States, there is a risk that some

of our confidential information could be compromised by disclosure during this type of litigation.

There could also be public announcements

of the results of hearings, motions or other interim proceedings or developments in any such proceedings.

If securities analysts

or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common

Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations, stock

price and prospects.

We may be subject to claims by third parties asserting

that our collaborators, employees or we have misappropriated their intellectual property, or claiming ownership of what we regard

as our own intellectual property.

Many of our employees, including our

senior management team, were previously employed at, or consulted for, universities or other biotechnology or pharmaceutical

companies, including our competitors or potential competitors.

Our collaborators’

employees may currently be or

previously have been employed at universities or other biotechnology or pharmaceutical companies, including our competitors

or potential competitors.

Some of these persons, including each member of our senior management team, executed proprietary

rights, nondisclosure and noncompetition agreements, or similar agreements, in connection with such previous employment or

consulting agreements, that assigned ownership of intellectual property relating to work performed under such agreements to

the contracting third party.

Although we take steps to ensure that our employees do not use, claim as theirs, or

misappropriate the intellectual property, proprietary information or know-how of others in their work for us, we may be

subject to claims that we or these employees have used, claimed as theirs, misappropriated or disclosed intellectual

property, including trade secrets or other proprietary information, of any such individual’s current or former

Litigation may be necessary to defend against such claims.

If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages.

Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products.

If we fail in defending any such claims, in addition to

paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages.

Such intellectual

property rights could be awarded to a third party, and we could be required to obtain a license from such third-party to

commercialize our technology or products.

Such a license may not be available on commercially reasonable terms, or at all.

Even if we are successful in defending against such claims, litigation could

result in substantial costs and be a distraction to management.

Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed confidential information of third parties or are in breach of noncompetition or nonsolicitation agreements with our competitors.

We could be subject to claims that we or our employees, including senior management, have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors or others.

Although we take steps to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we caused an employee to breach the terms of their noncompetition or nonsolicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor or other party.

Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction

to management.

Any of the foregoing may have a material adverse effect on our business, financial condition, results of

operations, stock price and prospects.

We may be subject to damages resulting from claims that

we or our employees have wrongfully used or disclosed confidential information of third parties or are in breach of noncompetition

or nonsolicitation agreements with our competitors.

We could be subject to claims that we or

our employees, including senior management, have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential

information of former employers or competitors or others.

Although we take steps to ensure that our employees and consultants do

not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be

subject to claims that we caused an employee to breach the terms of their noncompetition or nonsolicitation agreement, or that

we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information

of a former employer or competitor or other party.

Litigation may be necessary to defend against these claims.

Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management.

If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to RP1 and our other product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers, competitors or other parties.

An inability to incorporate such technologies or features would have a material adverse effect on our business, and may prevent us from successfully commercializing RP1 and our other product candidates.

In addition, we may lose valuable intellectual property rights or personnel as a result of such claims.

Moreover, any such litigation or the threat thereof may adversely affect our ability to hire employees or consultants.

A loss of key personnel or their work product could hamper or prevent our ability to develop and commercialize RP1 and our other product candidates, which could have an adverse effect on our business, financial condition, results of operations, stock price and prospects.

If we obtain any issued patents covering our technology, such patents could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign regulatory authority.

If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering any of our technology, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable.

In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent.

Grounds for a validity challenge could be, among other things, an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.

Grounds for an unenforceability assertion could be, among other things, an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution.

Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation.

Such mechanisms include reexamination, inter partes review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, such as opposition proceedings.

Such proceedings could result in revocation, cancellation or amendment of our patents in such a way that they no longer cover and protect RP1 and our other product candidates.

The outcome following legal assertions of invalidity and unenforceability is unpredictable.

For example, with respect to the validity of our licensed patents or any patents we obtain in the future, we cannot be certain that there is no invalidating prior art of which we, our or our licensing partners patent counsel, and the patent examiner were unaware during prosecution.

If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on RP1 and our other product candidates.

Even if we are successful

in defending against these claims, litigation could result in substantial costs and could be a distraction to management.

defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies

or features that are essential to RP1 and our other product candidates, if such technologies or features are found to incorporate

or be derived from the trade secrets or other proprietary information of the former employers, competitors or other parties.

inability to incorporate such technologies or features would have a material adverse effect on our business, and may prevent us

from successfully commercializing RP1 and our other product candidates.

In addition, we may lose valuable intellectual property

rights or personnel as a result of such claims.

Moreover, any such litigation or the threat thereof may adversely affect our ability

to hire employees or consultants.

A loss of key personnel or their work product could hamper or prevent our ability to develop

and commercialize RP1 and our other product candidates, which could have an adverse effect on our business, financial condition,

results of operations, stock price and prospects.

If we obtain any issued patents covering our technology,

such patents could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign regulatory

If we or one of our licensing partners initiate

legal proceedings against a third party to enforce a patent covering any of our technology, the defendant could counterclaim that

the patent covering our product candidate is invalid or unenforceable.

In patent litigation in the United States, defendant counterclaims

alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity

or unenforceability of a patent.

Grounds for a validity challenge could be, among other things, an alleged failure to meet any

of several statutory requirements, including lack of novelty, obviousness, or non-enablement.

Grounds for an unenforceability assertion

could be, among other things, an allegation that someone connected with prosecution of the patent withheld relevant information

from the USPTO, or made a misleading statement, during prosecution.

Third parties may also raise similar claims before administrative

bodies in the United States or abroad, even outside the context of litigation.

Such mechanisms include reexamination, inter

partes review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions,

such as opposition proceedings.

Such proceedings could result in revocation, cancellation or amendment of our patents in such a

way that they no longer cover and protect RP1 and our other product candidates.

The outcome following legal assertions of invalidity

and unenforceability is unpredictable.

For example, with respect to the validity of our licensed patents or any patents we obtain

in the future, we cannot be certain that there is no invalidating prior art of which we, our or our licensing partners’

counsel, and the patent examiner were unaware during prosecution.

If a third party were to prevail on a legal assertion of invalidity

and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on RP1 and our other product candidates.

Such a loss of patent protection could have a material adverse impact on our business.

Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and our product candidates for which we intend to seek approval as biological products may face competition sooner than anticipated.

Given the amount of time required for the development, testing and regulatory review of new product candidates, such as RP1 and our other product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.

In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, but no longer than 14 years from the products approval date, which is limited to the approved indication (or any additional indications approved during the period of extension).

However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authorities in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request.

If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their products earlier than might otherwise be the case, which could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

The enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, as part of the Patient Protection and Affordable Care Act, or ACA, created an abbreviated pathway for the approval of biosimilar and interchangeable biological products.

The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics,

including the possible designation of a biosimilar as interchangeable based on its similarity to an existing brand product.

Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA.

Certain changes, however, and supplements to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or other related entity do not qualify for the 12 year exclusivity period.

RP1 and our other product candidates are all biological product candidates.

We anticipate being awarded market exclusivity for each of our biological product candidates that is subject to its own BLA for 12 years in the United States, 10 years in Europe and significant durations in other markets.

However, the term of the patents that cover such product candidates may not extend beyond the applicable market exclusivity awarded by a particular country.

For example, in the United States, if all of the patents that cover our particular biological product expire before the 12 year market exclusivity expires, a third party could submit a marketing application for a biosimilar product four years after approval of our biological product, the FDA could immediately review the application and approve the biosimilar product for marketing 12 years after approval of our biological product, and the biosimilar sponsor could then immediately begin marketing.

Alternatively, a third party could submit a full BLA for a similar or identical product any time after approval of our biological product, and the FDA could immediately review and approve the similar or identical product for marketing and the third party could begin marketing the similar or identical product upon expiry of all of the patents that cover our particular biological product.

There is also a risk that this exclusivity could be changed in the future.

For example, this exclusivity could be shortened due to congressional action or through other actions, including future proposed budgets, international trade agreements and other arrangements or proposals.

Additionally, there is a risk that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated.

The extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

It is also possible that payers will give reimbursement preference to biosimilars over reference biologics, even absent a determination of interchangeability.

To the extent that we do not receive any anticipated periods of regulatory exclusivity for our product candidates or the FDA or foreign regulatory authorities approve any biosimilar, interchangeable, or other competing products to our product candidates, it could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

Risks related to manufacturing and our reliance on third parties

We have agreements with BMS and Regeneron, and in the future may have agreements with other companies, to obtain the supply of anti-PD-1 therapies for the development of our other product candidates.

If our relationships with BMS, Regeneron, or any future collaborator or supplier are not successful, we may be delayed in completing the development of our other product candidates.

We have entered into arrangements with BMS and Regeneron as part of our clinical development for RP1 and RP2.

BMS is providing nivolumab, its anti-PD-1 therapy, for use in our ongoing Phase 1/2 clinical trials with RP1 and RP2 and Regeneron is providing cemiplimab, its anti-PD-1 therapy, for use in our randomized, controlled Phase 2 clinical trial with RP1 in approximately 240 patients with CSCC and may potentially do so for other clinical trials in the future.

We may also enter into agreements with additional companies for the supply of anti-PD-1 therapies for use in the development of RP1 and our other product candidates.

The outcome of these clinical trials is dependent both on the performance of our partners products and product candidates and also on our partners ability to deliver sufficient quantities of adequately produced product.

Should any of our partners products or product candidates fail to produce the results that we anticipate, we may have to rerun clinical trials for RP1 or our other product candidates or may otherwise be delayed in the commercialization of RP1 or our other product candidates.

Similarly, should any partner fail to provide us with a product or product candidate that suits our requirements we may have to re-run clinical trials for RP1 or our other product candidates or may be otherwise delayed in the commercialization of RP1 or our other product candidates.

Our collaboration agreements with any future partners may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.

We may in the future seek collaboration arrangements with other parties for the development or commercialization of our product candidates.

The success of any collaboration arrangements may depend on the efforts and activities of our collaborators.

Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these arrangements.

Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement.

These disagreements can be difficult to resolve if neither of the parties has final decision making authority.

Collaborations with biopharmaceutical companies and other third parties often are terminated or allowed to expire by the other party.

Any such termination or expiration could adversely affect us financially and could harm our business reputation.

Any future collaborations we might enter into may pose a number of risks, including the following:

Patent terms may be inadequate to protect our competitive

position on our products for an adequate amount of time, and our product candidates for which we intend to seek approval as biological

products may face competition sooner than anticipated.

Given the amount of time required for the

development, testing and regulatory review of new product candidates, such as RP1 and our other product candidates, patents protecting

such product candidates might expire before or shortly after such product candidates are commercialized.

In the United States,

the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the

normal expiration of the patent, but no longer than 14 years from the product’s approval date, which is limited to the

approved indication (or any additional indications approved during the period of extension).

However, the applicable authorities,

including the FDA and the USPTO in the United States, and any equivalent regulatory authorities in other countries, may not agree

with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more

limited extensions than we request.

If this occurs, our competitors may be able to take advantage of our investment in development

and clinical trials by referencing our clinical and preclinical data and launch their products earlier than might otherwise be

the case, which could have a material adverse effect on our business, financial condition, results of operations, stock price and

The enactment of the Biologics Price Competition

and Innovation Act of 2009, or BPCIA, as part of the Patient Protection and Affordable Care Act, or ACA, created an abbreviated

pathway for the approval of biosimilar and interchangeable biological products.

The abbreviated regulatory pathway establishes

legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as “interchangeable”

based on its similarity to an existing brand product.

Under the BPCIA, an application for a biosimilar product cannot be approved

by the FDA until 12 years after the original branded product was approved under a BLA.

Certain changes, however, and supplements

to an approved BLA, and subsequent applications filed by the same sponsor, manufacturer, licensor, predecessor in interest, or

other related entity do not qualify for the 12-year exclusivity period.

RP1 and our other product candidates are

all biological product candidates.

We anticipate being awarded market exclusivity for each of our biological product candidates

that is subject to its own BLA for 12 years in the United States, 10 years in Europe and significant durations in other

However, the term of the patents that cover such product candidates may not extend beyond the applicable market exclusivity

awarded by a particular country.

For example, in the United States, a third party could submit a marketing application for a biosimilar

product four years after approval of our biological product, the FDA could immediately review the application and approve the biosimilar

product for marketing 12 years after approval of our biological product, and if all of the patents that cover our particular

biological product expire before the 12 year market exclusivity expires, the biosimilar sponsor could then immediately begin marketing.

Alternatively, a third party could submit a full BLA for a similar or identical product any time after approval of our biological

product, and the FDA could immediately review and approve the similar or identical product for marketing and the third party could

begin marketing the similar or identical product upon expiry of all of the patents that cover our particular biological product.

There is also a risk that this exclusivity

could be changed in the future.

For example, this exclusivity could be shortened due to congressional action or through other actions,

including future proposed budgets, international trade agreements and other arrangements or proposals.

Additionally, there is a

risk that the FDA will not consider our product candidates to be reference products for competing products, potentially creating

the opportunity for biosimilar competition sooner than anticipated.

The extent to which a biosimilar, once approved, will be substituted

for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products

is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

It is also possible

that payers will give reimbursement preference to biosimilars over reference biologics, even absent a determination of interchangeability.

To the extent that we do not receive any

anticipated periods of regulatory exclusivity for our product candidates or the FDA or foreign regulatory authorities approve any

biosimilar, interchangeable, or other competing products to our product candidates, it could have a material adverse effect on

our business, financial condition, results of operations, stock price and prospects.

Risks related to manufacturing and our reliance on third

We have agreements with BMS and Regeneron, and in the

future may have agreements with other companies, to obtain the supply of anti-PD-1 therapies for the development of our product

If our relationships with BMS, Regeneron, or any future collaborator or supplier are not successful, we may be delayed

in completing the development of our product candidates.

We have entered into arrangements with BMS

and Regeneron as part of our clinical development for RP1 and RP2.

BMS is providing nivolumab, its anti-PD-1 therapy, for use in

our ongoing Phase 1/2 clinical trials with RP1 and RP2 and Regeneron is providing cemiplimab, its anti-PD-1 therapy, for use in

our randomized, controlled Phase 2 clinical trial with RP1 in approximately 240 patients with CSCC and may potentially do

so for other clinical trials in the future.

We may also enter into agreements with additional companies for the supply of anti-PD-1

therapies for use in the development of RP1 and our other product candidates.

The outcome of these clinical trials is dependent

both on the performance of our partners’

products and product candidates and also on our partners’

ability to deliver

sufficient quantities of adequately produced product.

Should any of our partners’

products or product candidates fail to

produce the results that we anticipate, we may have to re-run clinical trials for RP1 or our other product candidates or may otherwise

be delayed in the commercialization of RP1 or our other product candidates.

Similarly, should any partner fail to provide us with

a product or product candidate that suits our requirements, we may have to re-run clinical trials for RP1 or our other product

candidates or may be otherwise delayed in the commercialization of RP1 or our other product candidates.

Our collaboration agreements with any future partners

may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.

We may in the future seek collaboration

arrangements with other parties for the development or commercialization of our product candidates.

The success of any collaboration

arrangements may depend on the efforts and activities of our collaborators.

Collaborators generally have significant discretion

in determining the efforts and resources that they will apply to these arrangements.

Disagreements between parties to a collaboration

arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing

the applicable product candidate and, in some cases, termination of the collaboration arrangement.

These disagreements can be difficult

to resolve if neither of the parties has final decision-making authority.

Collaborations with biopharmaceutical companies

and other third parties often are terminated or allowed to expire by the other party.

Any such termination or expiration could

adversely affect us financially and could harm our business reputation.

Any future collaborations we might enter

into may pose a number of risks, including the following:

● collaborators may not perform their obligations as expected;

· collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;

· collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;

● collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or

may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’

strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;

● collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or

abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical

● collaborators could fail to make timely regulatory submissions for a product candidate;

· collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with all applicable regulatory requirements, which could subject them or us to regulatory enforcement actions;

· collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;

· product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;

· a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidate or product;

· disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time consuming and expensive;

· collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;

· collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.

If any collaborations we might enter into in the future do not result in the successful development and commercialization of products or if one of our collaborators subsequently terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such potential future collaboration.

If we do not receive the funding we expect under the agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates and our product platform.

Additionally, if any future collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization of any product candidate it licenses to us.

If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial communities could be adversely affected.

We face significant competition in seeking appropriate collaborators.

Our ability to reach a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborators resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborators evaluation of a number of factors.

If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense.

If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all.

If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product platform and our business may be materially and adversely affected.

We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials.

If those third parties do not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements, we may be unable to obtain regulatory approval for our product candidates or any other product candidates that we may develop in the future.

We rely on third party CROs, study sites, and others to conduct, supervise, and monitor our preclinical studies and clinical trials for our product candidates and do not currently plan to independently conduct preclinical studies or clinical trials of any other potential product candidates.

We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct our preclinical studies and clinical trials.

Although we have agreements governing their activities, we have limited influence over their actual performance and control only certain aspects of their activities.

The failure of these third parties to successfully carry out their contractual duties or meet expected deadlines could substantially harm our business because we may be delayed in completing or unable to complete the studies required to support future approval of our product candidates, or we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all.

Moreover, these agreements might terminate for a variety of reasons, including a failure to perform by the third parties.

If we need to enter into alternative arrangements our product development activities would be delayed and our business, financial condition, results of operations, stock price and prospects may be materially harmed.

Our reliance on these third parties for development activities will reduce our control over these activities.

Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities.

For example, we will remain responsible for ensuring that each of our trials is conducted in accordance with the general investigational plan and protocols for the trial.

We must also ensure that our preclinical trials are conducted in accordance with the FDAs Good Laboratory Practice, or GLP, regulations, as appropriate.

Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, commonly referred to as GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected.

Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites.

If we or any of our third parties fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement or other legal actions, the data generated in our trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional studies.

In addition, we will be required to report certain financial interests of our third party investigators if these relationships exceed certain financial thresholds or meet other criteria.

The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical trials conducted by investigators who may have conflicts of interest.

We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our trials complies with the applicable regulatory requirements.

● collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance with

all applicable regulatory requirements, which could subject them or us to regulatory enforcement actions;

● collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with

our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed

or can be commercialized under terms that are more economically attractive than ours;

● product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product

candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;

● a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval

may not commit sufficient resources to the marketing and distribution of such product candidate or product;

● disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred

course of development, might cause delays or termination of the research, development or commercialization of product candidates,

might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration,

any of which would be time consuming and expensive;

● collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in

such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or

expose us to potential litigation;

● collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential

If any collaborations we might enter into

in the future do not result in the successful development and commercialization of products or if one of our collaborators subsequently

terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such potential

future collaboration.

If we do not receive the funding we expect under the agreements, our development of our product candidates

could be delayed and we may need additional resources to develop our product candidates and our product platform.

Additionally, if any future collaborator

of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization

of any product candidate it licenses to us.

If one of our collaborators terminates its agreement with us, we may find it more difficult

to attract new collaborators and our reputation in the business and financial communities could be adversely affected.

We face significant competition in seeking

appropriate collaborators.

Our ability to reach a definitive agreement for any collaboration will depend upon, among other things,

our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and

the proposed collaborator’s evaluation of a number of factors.

If we are unable to reach agreements with

suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate,

reduce or delay its development program or one or more of our other development programs, delay its potential commercialization

or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization

activities at our own expense.

If we elect to fund and undertake development or commercialization activities on our own, we may

need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all.

we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization

activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our product

platform and our business may be materially and adversely affected.

We rely, and expect to continue to rely, on third parties

to conduct, supervise, and monitor our preclinical studies and clinical trials.

If those third parties do not perform satisfactorily,

including failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements, we may

be unable to obtain regulatory approval for our product candidates or any other product candidates that we may develop in the future.

We rely on third-party CROs, study sites,

and others to conduct, supervise, and monitor our preclinical studies and clinical trials for our product candidates and do not

currently plan to independently conduct preclinical studies or clinical trials of any other potential product candidates.

to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical

investigators, to conduct our preclinical studies and clinical trials.

Although we have agreements governing their activities,

we have limited influence over their actual performance and control only certain aspects of their activities.

The failure of these

third parties to successfully carry out their contractual duties or meet expected deadlines could substantially harm our business

because we may be delayed in completing or unable to complete the studies required to support future approval of our product candidates,

or we may not obtain marketing approval for or commercialize our product candidates in a timely manner or at all.

Moreover, these

agreements might terminate for a variety of reasons, including a failure to perform by the third parties.

If we need to enter into

alternative arrangements our product development activities would be delayed and our business, financial condition, results of

operations, stock price and prospects may be materially harmed.

Our reliance on these third parties for

development activities will reduce our control over these activities.

Nevertheless, we are responsible for ensuring that each of

our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance

on third parties does not relieve us of our regulatory responsibilities.

For example, we will remain responsible for ensuring that

each of our trials is conducted in accordance with the general investigational plan and protocols for the trial.

We must also ensure

that our preclinical trials are conducted in accordance with the FDA’s Good Laboratory Practice, or GLP, regulations, as

Moreover, the FDA and comparable foreign regulatory authorities require us to comply with standards, commonly referred

to as GCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are

credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected.

Regulatory authorities

enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites.

of our third parties fail to comply with applicable GCPs or other regulatory requirements, we or they may be subject to enforcement

or other legal actions, the data generated in our trials may be deemed unreliable and the FDA or comparable foreign regulatory

authorities may require us to perform additional studies.

In addition, we will be required to report

certain financial interests of our third-party investigators if these relationships exceed certain financial thresholds or meet

other criteria.

The FDA or comparable foreign regulatory authorities may question the integrity of the data from those clinical

trials conducted by investigators who may have conflicts of interest.

We cannot assure you that upon inspection

by a given regulatory authority, such regulatory authority will determine that any of our trials complies with the applicable regulatory

requirements.

In addition, our clinical trials must be conducted with product candidates that were produced under cGMP regulations.

Failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government sponsored database, ClinicalTrials.gov, within specified timeframes.

Failure to do so can result in enforcement actions and adverse publicity.

The third parties with which we work may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting trials or other therapeutic development activities that could harm our competitive position.

In addition, such third parties are not our employees, and except for remedies available to us under our agreements with such third parties we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, nonclinical, and preclinical programs.

If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be replaced or if

the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols, regulatory requirements or for other reasons, our trials may be repeated, extended, delayed, or terminated;

we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates;

we may not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates, or we or they may be subject to regulatory enforcement actions.

As a result, our results of

operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.

To the extent we are unable to successfully identify and manage the performance of third party service providers in the future, our business, financial condition, results of operations, stock price and prospects may be materially harmed.

If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative providers or to do so on commercially reasonable terms.

We also are required to register certain clinical trials and post the results of certain completed clinical trials on a government

sponsored database, ClinicalTrials.gov, within specified timeframes.

Failure to do so can result in enforcement actions and adverse

The third parties with which we work

may also have relationships with other entities, some of which may be our competitors, for whom they may also be conducting

trials or other therapeutic development activities that could harm our competitive position.

In addition, such third parties

are not our employees, and except for remedies available to us under our agreements with such third parties we cannot control

whether or not they devote sufficient time and resources to our ongoing clinical, nonclinical, and preclinical programs.

these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our

preclinical studies or clinical trials in accordance with regulatory requirements or our stated protocols, if they need to be

replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our protocols,

regulatory requirements or for other reasons, our trials may be repeated, extended, delayed, or terminated;

we may not be

able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates;

we may not be able to, or may

be delayed in our efforts to, successfully commercialize our product candidates, or we or they may be subject to regulatory

enforcement actions.

As a result, our results of operations and the commercial prospects for our product candidates would be

harmed, our costs could increase and our ability to generate revenues could be delayed.

To the extent we are unable to

successfully identify and manage the performance of third-party service providers in the future, our business, financial

condition, results of operations, stock price and prospects may be materially harmed.

If any of our relationships with these third

parties terminate, we may not be able to enter into arrangements with alternative providers or to do so on commercially reasonable

Switching or adding additional third parties involves additional cost and requires management time and focus.

In addition, there is a natural transition period when a new third party commences work.

As a result, delays could occur, which could compromise our ability to meet our desired development timelines.

We also rely on other third parties to store and distribute our products for the clinical trials that we conduct.

Any performance failure on the part of our distributors could delay clinical development, marketing approval, or commercialization of our product candidates, which could result in additional losses and deprive us of potential product revenue.

If the manufacturers upon which we rely fail to produce our product candidates in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to biopharmaceutical manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand for, our product candidates and may lose potential revenues.

Until our manufacturing facility is fully operational and for period of time thereafter, we will rely on third party contract manufacturers to manufacture our clinical trial product supplies.

There can be no assurance that our clinical development will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices.

In particular, any replacement of our contract manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements.

Any delays in obtaining adequate supplies of our product candidates that meet the necessary quality standards may delay our development or commercialization.

We may not succeed in our efforts to establish manufacturing relationships or other alternative arrangements for any of our product candidates or programs.

Our product candidates may compete with other products and product candidates for access to manufacturing facilities.

There are a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing and filling our viral product for us and willing to do so.

If our existing third party manufacturers, or the third parties that we engage in the future, should cease to work with us, we likely would experience delays in obtaining sufficient quantities of our product candidates for us to meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers.

If for any reason we are unable to obtain adequate supplies of our product candidates or the therapeutic substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.

Further, even if we do establish such collaborations or arrangements, our third party manufacturers may breach, terminate, or not renew these agreements.

Any problems or delays we experience in preparing for commercial scale manufacturing of a product candidate or component may result in a delay in product development timelines and FDA or comparable foreign regulatory authority approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost and quality, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and may materially harm our business, financial condition, results of operations, stock price and prospects.

We currently have only one contract manufacturer for our product candidates for use in our clinical trials.

In addition, we do not have any long term commitments from our suppliers of clinical trial material or guaranteed prices for our product candidates or their components.

The manufacture of biopharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls.

Manufacturers of therapeutics often encounter difficulties in production, particularly in scaling up initial production.

These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations.

there is a natural transition period when a new third party commences work.

As a result, delays could occur, which could compromise

our ability to meet our desired development timelines.

We also rely on other third parties to store

and distribute our products for the clinical trials that we conduct.

Any performance failure on the part of our distributors could

delay clinical development, marketing approval, or commercialization of our product candidates, which could result in additional

losses and deprive us of potential product revenue.

If the manufacturers upon which we rely fail to produce

our product candidates in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable

to biopharmaceutical manufacturers, we may face delays in the development and commercialization of, or be unable to meet demand

for, our product candidates and may lose potential revenues.

Until our manufacturing facility is fully

operational and for a period of time thereafter, we will rely on third-party contract manufacturers to manufacture our clinical

trial product supplies.

There can be no assurance that our clinical development will not be limited, interrupted, or of satisfactory

quality or continue to be available at acceptable prices.

In particular, any replacement of our contract manufacturer could require

significant effort and expertise because there may be a limited number of qualified replacements.

Any delays in obtaining adequate

supplies of our product candidates that meet the necessary quality standards may delay our development or commercialization.

We may not succeed in our efforts to establish

manufacturing relationships or other alternative arrangements for any of our product candidates or programs.

Our product candidates

may compete with other products and product candidates for access to manufacturing facilities.

There are a limited number of manufacturers

that operate under cGMP regulations and that are both capable of manufacturing and filling our viral product for us and willing

If our existing third-party manufacturers, or the third parties that we engage in the future, should cease to work with

us, we likely would experience delays in obtaining sufficient quantities of our product candidates for us to meet commercial demand

or to advance our clinical trials while we identify and qualify replacement suppliers.

If for any reason we are unable to obtain

adequate supplies of our product candidates or the therapeutic substances used to manufacture them, it will be more difficult for

us to develop our product candidates and compete effectively.

Further, even if we do establish such collaborations or arrangements,

our third-party manufacturers may breach, terminate, or not renew these agreements.

Any problems or delays we experience in

preparing for commercial scale manufacturing of a product candidate or component may result in a delay in product development timelines

and FDA or comparable foreign regulatory authority approval of the product candidate or may impair our ability to manufacture commercial

quantities or such quantities at an acceptable cost and quality, which could result in the delay, prevention, or impairment of

clinical development and commercialization of our product candidates and may materially harm our business, financial condition,

results of operations, stock price and prospects.

We currently have only one contract manufacturer

for our product candidates for use in our clinical trials.

In addition, we do not have any long-term commitments from our suppliers

of clinical trial material or guaranteed prices for our product candidates or their components.

The manufacture of biopharmaceutical

products requires significant expertise and capital investment, including the development of advanced manufacturing techniques

and process controls.

Manufacturers of therapeutics often encounter difficulties in production, particularly in scaling up initial

These problems include difficulties with production costs and yields, quality control, including stability of the product

candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced

federal, state, and foreign regulations.

Our contract manufacturers may not perform as agreed.

If our manufacturers were to encounter these or other difficulties, our ability to provide product candidates to patients in our clinical trials could be jeopardized.

Contract manufacturers of our product candidates may be unable to comply with our specifications, applicable cGMP requirements or other FDA, state or foreign regulatory requirements.

Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of a product candidate that may not be detectable in final product testing.

If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure or

maintain regulatory approval for their manufacturing facilities.

Any such deviations may also require remedial measures that may be costly and/or time consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or the temporary or permanent closure of a facility.

If our manufacturers were to encounter

these or other difficulties, our ability to provide product candidates to patients in our clinical trials could be jeopardized.

Contract manufacturers of our product candidates

may be unable to comply with our specifications, applicable cGMP requirements or other FDA, state or foreign regulatory requirements.

Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent

changes in the properties or stability of a product candidate that may not be detectable in final product testing.

If our contract

manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements

of the FDA or other regulatory authorities, they will not be able to secure or maintain regulatory approval for their manufacturing

Any such deviations may also require remedial measures that may be costly and/or time consuming for us or a third party

to implement and that may include the temporary or permanent suspension of a clinical trial or the temporary or permanent closure

of a facility.

Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.

Any delays in obtaining products or product candidates that comply with the

applicable regulatory requirements may result in delays to clinical trials, product approvals, and commercialization.

Any delays in obtaining products or product candidates that comply with the applicable regulatory requirements may result in delays

to clinical trials, product approvals, and commercialization.

It may also require that we conduct additional studies.

While we are ultimately responsible for the manufacturing of our product candidates and therapeutic substances, other than through our contractual arrangements, we have little control over our manufacturers compliance with these regulations and standards.

If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.

Any new manufacturers would need to either obtain or develop the necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take substantial time and investment.

While we are ultimately responsible for

the manufacturing of our product candidates and therapeutic substances, other than through our contractual arrangements, we have

little control over our manufacturers’

compliance with these regulations and standards.

If the FDA or a comparable foreign

regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such

approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability

to develop, obtain regulatory approval for or market our product candidates, if approved.

Any new manufacturers would need to either

obtain or develop the necessary manufacturing know-how, and obtain the necessary equipment and materials, which may take substantial

time and investment.

We must also receive FDA approval for the use of any new manufacturers for commercial supply.

A failure to comply with the applicable regulatory requirements, including periodic regulatory inspections, may result in regulatory enforcement actions against our manufacturers or us (including fines and civil and criminal penalties, including imprisonment) suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the product candidate, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the civil False Claims Act, corporate integrity agreements, consent decrees, withdrawal of product approval, environmental or safety incidents and other liabilities.

If the safety of any quantities supplied is compromised due to our manufacturers failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.

Any failure or refusal to supply our product candidates or components for our product candidates that we may develop could delay, prevent or impair our clinical development or commercialization efforts.

Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.

The transition of our manufacturing operations to our new facility may result in further delays or expenses, and we may not experience the anticipated operating efficiencies.

We have completed the build-out of, and obtained an occupancy certificate with respect to, our approximately 63,000 square foot manufacturing facility in Framingham, Massachusetts at which we intend operate our own manufacturing facility in order to secure supplies for pivotal studies and commercial launch.

This facility is intended to give us control over key aspects of the supply chain for our products and product candidates.

We may not experience the anticipated operating efficiencies as we commence manufacturing operations at the new facility.

Any such delays may disrupt or delay the supply of our product candidates if we have not maintained a sufficient backup supply of our product candidates through third party manufacturers.

Moreover, changing manufacturing facilities may also require that we conduct additional studies, make notifications to the regulatory authorities, make additional filings to the regulatory authorities, and obtain regulatory authority approval for the new facilities, which may be delayed or which we may never receive.

We will further need to comply with the FDAs and applicable foreign regulatory authorities cGMP requirements for the production of our product candidates for clinical trials and, if approved, commercial supply, and will be subject to FDA and comparable foreign regulatory authority inspection.

These requirements include the qualification and validation of our manufacturing equipment and processes.

We may not be able to develop or acquire the internal expertise and resources necessary for compliance with these requirements.

If we fail to achieve the operating efficiencies that we anticipate, our manufacturing and operating costs may be greater than expected, which could have a material adverse impact on our operating results.

In operating our own manufacturing facility, we may be forced to devote greater resources and management time than anticipated, particularly in areas relating to operations, quality, regulatory, facilities and information technology.

If we experience unanticipated employee turnover in any of these areas, we may not be able to effectively manage our ongoing manufacturing operations and we may not achieve the operating efficiencies that we anticipate from the new facility, which may negatively affect our product development timeline.

Any such problems could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates and may materially harm our business, financial condition, results of operations, stock price and prospects.

A failure to comply with the applicable

regulatory requirements, including periodic regulatory inspections, may result in regulatory enforcement actions against our manufacturers

or us (including fines and civil and criminal penalties, including imprisonment) suspension or restrictions of production, injunctions,

delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning

or untitled letters, regulatory authority communications warning the public about safety issues with the product candidate, refusal

to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the

civil False Claims Act, corporate integrity agreements, consent decrees, withdrawal of product approval, environmental or safety

incidents and other liabilities.

If the safety of any quantities supplied is compromised due to our manufacturers’

to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize

our product candidates.

Any failure or refusal to supply our product

candidates or components for our product candidates that we may develop could delay, prevent or impair our clinical development

or commercialization efforts.

Any change in our manufacturers could be costly because the commercial terms of any new arrangement

could be less favorable and because the expenses relating to the transfer of necessary technology and processes could be significant.

The transition of our manufacturing operations to our

new facility may result in further delays or expenses, and we may not experience the anticipated operating efficiencies.

We have completed the build-out of, obtained

an occupancy certificate with respect to, and successfully completed our first two tech transfers at, our approximately 63,000

square foot manufacturing facility in Framingham, Massachusetts at which we intend to operate our own manufacturing facility in

order to secure supplies for pivotal studies and commercial launch.

This facility is intended to give us control over key aspects

of the supply chain for our products and product candidates.

We may not experience the anticipated operating efficiencies as we

commence manufacturing operations at the new facility.

Any such delays may disrupt or delay the supply of our product candidates

if we have not maintained a sufficient backup supply of our product candidates through third-party manufacturers.

Moreover, changing

manufacturing facilities may also require that we conduct additional studies, make notifications to the regulatory authorities,

make additional filings to the regulatory authorities, and obtain regulatory authority approval for the new facilities, which may

be delayed or which we may never receive.

We will further need to comply with the FDA’s and applicable foreign regulatory

authorities’

cGMP requirements for the production of our product candidates for clinical trials and, if approved, commercial

supply, and will be subject to FDA and comparable foreign regulatory authority inspection.

These requirements include the qualification

and validation of our manufacturing equipment and processes.

We may not be able to develop or acquire the internal expertise and

resources necessary for compliance with these requirements.

If we fail to achieve the operating efficiencies that we anticipate,

our manufacturing and operating costs may be greater than expected, which could have a material adverse impact on our operating

In operating our own manufacturing facility,

we may be forced to devote greater resources and management time than anticipated, particularly in areas relating to operations,

quality, regulatory, facilities and information technology.

If we experience unanticipated employee turnover in any of these areas,

we may not be able to effectively manage our ongoing manufacturing operations and we may not achieve the operating efficiencies

that we anticipate from the new facility, which may negatively affect our product development timeline.

Any such problems could result in the delay,

prevention, or impairment of clinical development and commercialization of our product candidates and may materially harm our business,

financial condition, results of operations, stock price and prospects.

Risks related to legal and compliance matters

We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability and have to limit the commercialization of any approved products and/or our product candidates.

The use of our product candidates in clinical trials, and the sale of any product for which we obtain regulatory approval, exposes us to the risk of product liability claims.

We face inherent risk of product liability related to the testing of our product

candidates in human clinical trials, including liability relating to the actions and negligence of our investigators, and will face an even greater risk if we commercially sell any product candidates that we may develop.

For example, we may be sued if any product candidate we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale.

Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties.

Claims could also be asserted under state consumer protection acts.

Product liability claims might be brought against us by consumers, healthcare providers or others using, administering or selling our products.

If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities or be required to limit commercialization of our product candidates.

We face potential product liability exposure, and if successful

claims are brought against us, we may incur substantial liability and have to limit the commercialization of any approved products

and/or our product candidates.

The use of our product candidates in

clinical trials, and the sale of any product for which we obtain regulatory approval, exposes us to the risk of product

liability claims.

We face inherent risk of product liability related to the testing of our product candidates in human

clinical trials, including liability relating to the actions and negligence of our investigators, and will face an even

greater risk if we commercially sell any product candidates that we may develop.

For example, we may be sued if any product

candidate we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing,

marketing or sale.

Any such product liability claims may include allegations of defects in manufacturing, defects in design,

a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties.

also be asserted under state consumer protection acts.

Product liability claims might be brought against us by consumers,

healthcare providers or others using, administering or selling our products.

If we cannot successfully defend ourselves

against these claims, we will incur substantial liabilities or be required to limit commercialization of our product

Even successful defense would require significant financial and management resources.

Regardless of merit or eventual outcome, liability claims may result in:

Regardless of merit or

eventual outcome, liability claims may result in:

● loss of revenue from decreased demand for our products and/or product candidates;

9 unchanged sentences

● product recalls, withdrawals or labeling, marketing or promotional restrictions, including withdrawal of marketing approval.

We believe we have sufficient insurance coverage in place for our business operations.

However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer.

Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.

We intend to expand our insurance coverage to include the sale of commercial products if we obtain FDA or comparable foreign regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing, or at all.

Failure to obtain and retain sufficient product liability insurance at an acceptable cost could prevent or inhibit the commercialization of products we develop.

On occasion, large judgments have been awarded in class action lawsuits based on therapeutics that had unanticipated side effects.

A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash, and materially harm our business, financial condition, results of operations, stock price and prospects.

We believe we have sufficient insurance

coverage in place for our business operations.

However, our insurance coverage may not reimburse us or may not be sufficient to

reimburse us for any expenses or losses we may suffer.

Moreover, insurance coverage is becoming increasingly expensive and, in

the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against

losses due to liability.

We intend to expand our insurance coverage to include the sale of commercial products if we obtain FDA

or comparable foreign regulatory approval for our product candidates in development, but we may be unable to obtain commercially

reasonable product liability insurance for any products approved for marketing, or at all.

Failure to obtain and retain sufficient

product liability insurance at an acceptable cost could prevent or inhibit the commercialization of products we develop.

large judgments have been awarded in class action lawsuits based on therapeutics that had unanticipated side effects.

product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our

insurance coverage, could decrease our cash, and materially harm our business, financial condition, results of operations, stock

price and prospects.

We are subject to the U.S.

Foreign Corrupt Practices Act, the U.K.

Bribery Act and other anticorruption laws, as well as import and export control laws, customs laws, sanctions laws and other laws governing our operations.

If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations, stock price and prospects.

Our operations are subject to anticorruption laws, including the U.S.

Foreign Corrupt Practices Act,

Bribery Act and other anticorruption laws, as well as import and export control laws, customs laws, sanctions laws and

other laws governing our operations.

If we fail to comply with these laws, we could be subject to civil or criminal penalties,

other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations,

stock price and prospects.

Our operations are subject to anticorruption

laws, including the U.S.

Foreign Corrupt Practices Act, or FCPA, the U.K.

Bribery Act 2010, or the Bribery Act, and other anticorruption laws that apply in countries where we do business.

The FCPA, the Bribery Act, and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage.

We also may participate in collaborations and relationships with third parties whose actions, if noncompliant, could potentially subject us to liability under the FCPA, Bribery Act or local anticorruption laws.

In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.

We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and the United Kingdom and authorities in the European Union, including applicable import

and export control regulations, economic sanctions on countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as the trade control laws.

We can provide no assurance that we will be completely effective in ensuring our compliance with all applicable anticorruption laws or other legal requirements, including trade control laws.

If we are not in compliance with applicable anticorruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations, stock price and prospects.

Likewise, any investigation of any potential violations of these anticorruption laws or trade control laws by U.S., U.K.

or other authorities could also have an adverse impact on our reputation, our business, financial condition, results of operations, stock price and prospects.

If we fail to comply with federal and state healthcare laws, including fraud and abuse and health and other information privacy and security laws, we could face substantial penalties and our business, financial condition, results of operations, stock price and prospects will be materially harmed.

We are subject to many federal and state healthcare laws, such as the federal Anti-Kickback Statute, the federal civil and criminal False Claims Acts, the civil monetary penalties statute, the Medicaid Drug Rebate statute and other price reporting requirements, the Veterans Health Care Act of 1992, or VHCA, the federal Health Insurance Portability and Accountability Act of 1996 (as amended by the Health Information Technology for Economics and Clinical Health Act, or HITECH), or HIPAA, the FCPA, the ACA, and similar state laws.

Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third party payors, certain federal and state healthcare laws, and regulations pertaining to fraud and abuse, reimbursement programs, government procurement, and patients rights are and will be applicable to our business.

We would be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business.

In the European Union, the data privacy laws are generally stricter than those that apply in the United States and include specific requirements for the collection of personal data of European Union persons or the transfer of personal data outside of the European Union to the United States to ensure that European Union standards of data privacy will be applied to such data.

If we or our operations are found to be in violation of any federal or state healthcare law, or any other governmental laws or regulations that apply to us, we may be subject to penalties, including civil, criminal, and administrative penalties, damages, fines, disgorgement, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in U.S.

federal or state health care programs, corporate integrity agreements, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results.

If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including but not limited to, exclusions from participation in government healthcare programs, which could also materially affect our business.

Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated.

Moreover, achieving and sustaining compliance with applicable federal, state and foreign privacy, data protection, security, reimbursement, and fraud laws may prove costly.

Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our managements attention from the operation of our business.

If the government or third party payors fail to provide adequate coverage, reimbursement and payment rates for our product candidates, or if health maintenance organizations or long-term care facilities choose to use therapies that are less expensive or considered a better value, our revenue and prospects for profitability will be limited.

In both domestic and foreign markets, sales of our products will depend in part upon the availability of coverage and reimbursement from third party payors.

Such third party payors include government health programs such as Medicare and Medicaid, managed care providers, private health insurers, and other organizations.

Coverage decisions may depend upon clinical and economic standards that disfavor new therapeutic products when more established or lower cost therapeutic alternatives are already available or subsequently become available, even if our products are alone in a class.

If reimbursement is not available, or is available only to limited levels, our product candidates may be competitively disadvantaged, and we may not be able to successfully commercialize our product candidates.

Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain a market share sufficient to realize a sufficient return on our or their investments.

Alternatively, securing favorable reimbursement terms may require us to compromise pricing and prevent us from realizing an adequate margin over cost.

There is significant uncertainty related to third party payor coverage and reimbursement of newly approved therapeutics.

Marketing approvals, pricing, and reimbursement for new therapeutic products vary widely from country to country.

Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in

obtaining approvals.

Some countries require approval of the sale price of a therapeutic before it can be marketed.

In many countries, the pricing review period begins after marketing or product licensing approval is granted.

In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted.

As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country.

Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.

Our ability to commercialize our product candidates will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.

Regulatory authorities and third party payors, such as private health insurers, and health maintenance organizations, decide which medications they will cover and establish reimbursement levels.

The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere.

Several third party payors are requiring that companies provide them with predetermined discounts from list prices, are using preferred drug lists to leverage greater discounts in competitive classes, are disregarding therapeutic differentiators within classes, are challenging the prices charged for therapeutics, and are negotiating price concessions based on performance goals.

Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs.

In addition, in the United States, no uniform policy of coverage and reimbursement for products exists among third party payors.

Therefore, coverage and reimbursement for products can differ significantly from payor to payor.

Further, we believe that future coverage and reimbursement will likely be subject to increased restrictions both in the United States and in international markets.

Third-party coverage and reimbursement for our products or product candidates for which we receive regulatory approval may not be available or adequate in either the United States or international markets, which could have a negative effect on our business, financial condition, results of operations, stock price and prospects.

Assuming coverage is approved, the resulting reimbursement payment rates might not be adequate.

If payors subject our product candidates to maximum payment amounts, or impose limitations that make it difficult to obtain reimbursement, providers may choose to use therapies which are less expensive when compared to our product candidates.

Bribery Act 2010, or the Bribery Act, and other anticorruption

laws that apply in countries where we do business.

The FCPA, the Bribery Act, and these other laws generally prohibit us and our

employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons

to obtain or retain business or gain some other business advantage.

We also may participate in collaborations and relationships

with third parties whose actions, if noncompliant, could potentially subject us to liability under the FCPA, Bribery Act or local

anticorruption laws.

In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our

international operations might be subject or the manner in which existing laws might be administered or interpreted.

We are also subject to other laws and regulations

governing our international operations, including regulations administered by the governments of the United States and the United

Kingdom and authorities in the European Union, including applicable import and export control regulations, economic sanctions on

countries and persons, anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred

to as the trade control laws.

We can provide no assurance that we will

be completely effective in ensuring our compliance with all applicable anticorruption laws or other legal requirements, including

trade control laws.

If we are not in compliance with applicable anticorruption laws or trade control laws, we may be subject to

criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse

impact on our business, financial condition, results of operations, stock price and prospects.

Likewise, any investigation of any

potential violations of these anticorruption laws or trade control laws by U.S., U.K.

or other authorities could also have an adverse

impact on our reputation, our business, financial condition, results of operations, stock price and prospects.

If we fail to comply with federal and state healthcare

laws, including fraud and abuse and health and other information privacy and security laws, we could face substantial penalties

and our business, financial condition, results of operations, stock price and prospects will be materially harmed.

We are subject to many federal and state

healthcare laws, such as the federal Anti-Kickback Statute, the federal civil and criminal False Claims Acts, the civil monetary

penalties statute, the Medicaid Drug Rebate statute and other price reporting requirements, the Veterans Health Care Act of 1992,

or VHCA, the federal Health Insurance Portability and Accountability Act of 1996 (as amended by the Health Information Technology

for Economics and Clinical Health Act, or HITECH), or HIPAA, the FCPA, the ACA, and similar state laws.

Even though we do not and

will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal

and state healthcare laws, and regulations pertaining to fraud and abuse, reimbursement programs, government procurement, and patients’

rights are and will be applicable to our business.

We would be subject to healthcare fraud and abuse and patient privacy regulation

by both the federal government and the states and foreign jurisdictions in which we conduct our business.

In the European Union,

the data privacy laws are generally stricter than those that apply in the United States and include specific requirements for the

collection of personal data of European Union persons or the transfer of personal data outside of the European Union to the United

States to ensure that European Union standards of data privacy will be applied to such data.

If we or our operations are found to be

in violation of any federal or state healthcare law, or any other governmental laws or regulations that apply to us, we may be

subject to penalties, including civil, criminal, and administrative penalties, damages, fines, disgorgement, suspension and debarment

from government contracts, and refusal of orders under existing government contracts, exclusion from participation in U.S.

or state health care programs, corporate integrity agreements, and the curtailment or restructuring of our operations, any of which

could materially adversely affect our ability to operate our business and our financial results.

If any of the physicians or other

healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may

be subject to criminal, civil or administrative sanctions, including but not limited to, exclusions from participation in government

healthcare programs, which could also materially affect our business.

Although an effective compliance program

can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated.

achieving and sustaining compliance with applicable federal, state and foreign privacy, data protection, security, reimbursement,

and fraud laws may prove costly.

Any action against us for violation of these laws, even if we successfully defend against it,

could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.

If the government or third- party payors fail to provide

adequate coverage, reimbursement and payment rates for our product candidates, or if health maintenance organizations or long-term

care facilities choose to use therapies that are less expensive or considered a better value, our revenue and prospects for profitability

will be limited.

In both domestic and foreign markets,

sales of our products will depend in part upon the availability of coverage and reimbursement from third-party payors.

third-party payors include government health programs such as Medicare and Medicaid, managed care providers, private health

insurers, and other organizations.

Coverage decisions may depend upon clinical and economic standards that disfavor new

therapeutic products when more established or lower cost therapeutic alternatives are already available or subsequently

become available, even if our products are alone in a class.

If reimbursement is not available, or is available only to

limited levels, our product candidates may be competitively disadvantaged, and we may not be able to successfully

commercialize our product candidates.

Even if coverage is provided, the approved reimbursement amount may not be high enough

to allow us to establish or maintain a market share sufficient to realize a sufficient return on our or their investments.

Alternatively, securing favorable reimbursement terms may require us to compromise pricing and prevent us from realizing an

adequate margin over cost.

There is significant uncertainty related

to third-party payor coverage and reimbursement of newly approved therapeutics.

Marketing approvals, pricing, and reimbursement

for new therapeutic products vary widely from country to country.

Current and future legislation may significantly change the approval

requirements in ways that could involve additional costs and cause delays in obtaining approvals.

Some countries require approval

of the sale price of a therapeutic before it can be marketed.

In many countries, the pricing review period begins after marketing

or product licensing approval is granted.

In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing

governmental control even after initial approval is granted.

As a result, we might obtain marketing approval for a product in a

particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy

time periods, which may negatively impact the revenues we are able to generate from the sale of the product in that country.

pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates

obtain marketing approval.

Our ability to commercialize our product candidates will depend in part on the extent to which coverage

and reimbursement for these products and related treatments will be available from government health administration authorities,

private health insurers and other organizations.

Regulatory authorities and third-party payors, such as private health insurers,

and health maintenance organizations, decide which medications they will cover and establish reimbursement levels.

The healthcare

industry is acutely focused on cost containment, both in the United States and elsewhere.

Several third-party payors are requiring

that companies provide them with predetermined discounts from list prices, are using preferred drug lists to leverage greater discounts

in competitive classes, are disregarding therapeutic differentiators within classes, are challenging the prices charged for therapeutics,

and are negotiating price concessions based on performance goals.

Third-party payors, whether foreign or domestic,

or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs.

in the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors.

coverage and reimbursement for products can differ significantly from payor to payor.

Further, we believe that future coverage

and reimbursement will likely be subject to increased restrictions both in the United States and in international markets.

coverage and reimbursement for our products or product candidates for which we receive regulatory approval may not be available

or adequate in either the United States or international markets, which could have a negative effect on our business, financial

condition, results of operations, stock price and prospects.

Assuming coverage is approved, the resulting

reimbursement payment rates might not be adequate.

If payors subject our product candidates to maximum payment amounts, or impose

limitations that make it difficult to obtain reimbursement, providers may choose to use therapies which are less expensive when

compared to our product candidates.

Additionally, if payors require high copayments, beneficiaries may seek alternative therapies.

We may need to conduct postmarketing studies in order to demonstrate the cost effectiveness of any products to the satisfaction of hospitals, other target customers and their third party payors.

Such studies might require us to commit a significant amount of management time and financial and other resources.

We may need to conduct post-marketing studies in order to demonstrate the cost effectiveness of any products to the satisfaction

of hospitals, other target customers and their third-party payors.

Such studies might require us to commit a significant amount

of management time and financial and other resources.

Our products might not ultimately be considered cost effective.

Adequate third party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.

In addition, federal programs impose penalties on manufacturers of therapeutics in the form of mandatory additional rebates and/or discounts if commercial prices increase at a rate greater than the Consumer Price Index Urban, and these rebates and/or discounts, which can be substantial, may impact our ability to raise commercial prices.

A few states have also passed or are considering legislation intended to prevent significant price increases.

Regulatory authorities and third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably.

These payors may not view our products, if any, as cost effective, and coverage and reimbursement may not be available to our customers, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis.

Cost control initiatives could cause us to decrease, discount, or rebate a portion of the price we, or they, might establish for products, which could result in lower than anticipated product revenues.

If the realized prices for our products, if any, decrease or if governmental and other third party payors do not provide adequate coverage or reimbursement, our prospects for revenue and profitability will suffer.

There may also be delays in obtaining coverage and reimbursement for newly approved therapeutics, and coverage may be more limited than the indications for which the product is approved by the FDA or comparable foreign regulatory authorities.

Such delays have made it increasingly common for manufacturers to provide newly approved drugs to patients experiencing coverage delays or disruption at no cost for a limited period in order to ensure that patients are able to access the drug.

Moreover, eligibility for reimbursement does not imply that any therapeutic will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution.

Interim reimbursement levels for new therapeutics, if applicable, may also not be sufficient to cover our costs and may only be temporary.

Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used.

Reimbursement rates may also be based on reimbursement levels already set for lower cost products or may be incorporated into existing payments for other services.

In addition, third party payors are increasingly requiring higher levels of evidence of the benefits and clinical outcomes of new technologies, benchmarking against other therapies, seeking performance-based discounts, and challenging the prices charged.

We cannot be sure that coverage will be available for any product candidate that we commercialize and, if available, that the reimbursement rates will be adequate.

An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.

We are subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance, and adversely affect our ability to market our products, obtain collaborators, and raise capital.

In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval.

We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved products.

For example, legislative changes have been proposed and adopted since the ACA was enacted in 2010.

These changes include, among other things, aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went effective on April 1, 2013.

In addition, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

The Centers for Medicare and Medicaid Services, or CMS, promulgated regulations governing manufacturers obligations and reimbursement under the Medicaid Drug Rebate Program, and recently promulgated a regulation that limited Medicare Part B payment to certain hospitals for outpatient drugs purchased under the 340B program.

These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our products, if approved, and, accordingly, on our results of operations.

We expect that the ACA, as well as other federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased net revenue from our biopharmaceutical products, decreased potential returns from our development efforts, and additional downward pressure on the price that we receive for any approved product.

Any reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments from private payors.

The implementation of cost containment measures or other healthcare reforms may prevent us from commercializing our products and being able to generate revenue, and we could be prevented from or significantly delayed in achieving profitability.

In addition, there have been a number of other legislative and regulatory proposals aimed at changing the biopharmaceutical industry.

For instance, the Drug Quality and Security Act imposes obligations on manufacturers of biopharmaceutical products related to product tracking and tracing.

Among the requirements of this legislation, manufacturers are required to provide certain information regarding the product to individuals and entities to which product ownership is transferred, will be required to label products with a product identifier, and are required to keep certain records regarding the product.

The transfer of information to subsequent product owners by manufacturers is also required to be done electronically.

Manufacturers are also being required to verify that purchasers of the manufacturers products are appropriately licensed.

Further, manufactures have product investigation, quarantine, disposition, and FDA, other comparable foreign regulatory authorities, and trading partner notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products that would result in serious adverse health consequences of death to humans, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.

Compliance with the federal track and trace requirements may increase our operational expenses and impose significant administrative burdens.

As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

Our employees, independent contractors, consultants, commercial partners, principal investigators, CMOs, or CROs may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.

We are exposed to the risk of employee fraud or other misconduct.

Misconduct by employees, independent contractors, consultants, commercial partners, principal investigators, CMOs, or CROs could include intentional, reckless, negligent, or unintentional failures to comply with FDA regulations, comply with applicable fraud and abuse laws, provide accurate information to the FDA, properly calculate pricing information required by federal programs, report financial information or data accurately or disclose unauthorized activities to us.

This misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.

It is not always possible to identify and deter this type of misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.

Moreover, it is possible for a whistleblower to pursue a False Claims Act case against us even if the government considers the claim unmeritorious and declines to intervene, which could require us to incur costs defending against such a claim.

If any such actions are instituted against us, and we are not successful

in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, stock price and prospects, including the imposition of significant fines or other sanctions.

Violations of or liabilities under environmental, health and safety laws and regulations could subject us to fines, penalties or other costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage, treatment and disposal of hazardous materials and wastes and the cleanup of contaminated sites.

Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials.

Our operations also produce hazardous waste products.

We would incur substantial costs as a result of violations of or liabilities under environmental requirements in connection with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third party claims.

Although we generally contract with third parties for the disposal of hazardous materials and wastes from our operations, we cannot eliminate the risk of contamination or injury from these materials.

In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.

third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate

return on investment in product development.

In addition, federal programs impose penalties

on manufacturers of therapeutics in the form of mandatory additional rebates and/or discounts if commercial prices increase at

a rate greater than the Consumer Price Index Urban, and these rebates and/or discounts, which can be substantial, may impact our

ability to raise commercial prices.

A few states have also passed or are considering legislation intended to prevent significant

price increases.

Regulatory authorities and third-party payors have attempted to control costs by limiting coverage and the amount

of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably.

may not view our products, if any, as cost effective, and coverage and reimbursement may not be available to our customers, or

may not be sufficient to allow our products, if any, to be marketed on a competitive basis.

Cost control initiatives could cause

us to decrease, discount, or rebate a portion of the price we, or they, might establish for products, which could result in lower

than anticipated product revenues.

If the realized prices for our products, if any, decrease or if governmental and other third-party

payors do not provide adequate coverage or reimbursement, our prospects for revenue and profitability will suffer.

There may also be delays in obtaining

coverage and reimbursement for newly approved therapeutics, and coverage may be more limited than the indications for which

the product is approved by the FDA or comparable foreign regulatory authorities.

Such delays have made it increasingly common

for manufacturers to provide newly approved drugs to patients experiencing coverage delays or disruption at no cost for a

limited period in order to ensure that patients are able to access the drug.

Moreover, eligibility for reimbursement does not

imply that any therapeutic will be paid for in all cases or at a rate that covers our costs, including research, development,

manufacture, sale, and distribution.

Interim reimbursement levels for new therapeutics, if applicable, may also not be

sufficient to cover our costs and may only be temporary.

Reimbursement rates may vary, by way of example, according to the

use of the product and the clinical setting in which it is used.

Reimbursement rates may also be based on reimbursement

levels already set for lower cost products or may be incorporated into existing payments for other services.

In addition, third-party payors are increasingly

requiring higher levels of evidence of the benefits and clinical outcomes of new technologies, benchmarking against other therapies,

seeking performance-based discounts, and challenging the prices charged.

We cannot be sure that coverage will be available for

any product candidate that we commercialize and, if available, that the reimbursement rates will be adequate.

An inability to promptly

obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for

which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital

needed to commercialize products and our overall financial condition.

We are subject to new legislation, regulatory proposals

and healthcare payor initiatives that may increase our costs of compliance, and adversely affect our ability to market our products,

obtain collaborators, and raise capital.

In the United States and some foreign jurisdictions,

there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could

prevent or delay marketing approval of our product candidates, restrict or regulate post approval activities and affect our ability

to profitably sell any products for which we obtain marketing approval.

We expect that current laws, as well as other healthcare

reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure

on the price that we may receive for any approved products.

For example, legislative changes have been

proposed and adopted since the ACA was enacted in 2010.

These changes include, among other things, aggregate reductions to Medicare

payments to providers of up to 2% per fiscal year, which went effective on April 1, 2013.

In addition, the American Taxpayer

Relief Act of 2012, among other things, further reduced Medicare payments to several providers and increased the statute of limitations

period for the government to recover overpayments to providers from three to five years.

The Centers for Medicare and Medicaid

Services, or CMS, promulgated regulations governing manufacturers’

obligations and reimbursement under the Medicaid Drug

Rebate Program, and promulgated a regulation that limited Medicare Part B payment to certain hospitals for outpatient drugs

purchased under the 340B program.

These new laws may result in additional reductions in Medicare and other healthcare funding,

which could have a material adverse effect on customers for our products, if approved, and, accordingly, on our results of operations.

We expect that the ACA, as well as other

federal and state healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria,

increased regulatory burdens and operating costs, decreased net revenue from our biopharmaceutical products, decreased potential

returns from our development efforts, and additional downward pressure on the price that we receive for any approved product.

reduction in reimbursement from Medicare or other government healthcare programs may result in a similar reduction in payments

from private payors.

The implementation of cost containment measures or other healthcare reforms may prevent us from commercializing

our products and being able to generate revenue, and we could be prevented from or significantly delayed in achieving profitability.

In addition, there have been a number of

other legislative and regulatory proposals aimed at changing the biopharmaceutical industry.

For instance, the Drug Quality and

Security Act imposes obligations on manufacturers of biopharmaceutical products related to product tracking and tracing.

the requirements of this legislation, manufacturers are required to provide certain information regarding the product to individuals

and entities to which product ownership is transferred, are required to label products with a product identifier, and are required

to keep certain records regarding the product.

The transfer of information to subsequent product owners by manufacturers is also

required to be done electronically.

Manufacturers are also being required to verify that purchasers of the manufacturers’

products are appropriately licensed.

Further, manufactures have product investigation, quarantine, disposition, and FDA, other

comparable foreign regulatory authorities, and trading partner notification responsibilities related to counterfeit, diverted,

stolen, and intentionally adulterated products that would result in serious adverse health consequences of death to humans, as

well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would

be reasonably likely to result in serious health consequences or death.

Compliance with the federal track and

trace requirements may increase our operational expenses and impose significant administrative burdens.

As a result of these

and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change

our contract arrangements, any of which could have a material adverse effect on our business, financial condition, results of

operations, stock price and prospects.

Our employees, independent contractors, consultants, commercial

partners, principal investigators, CMOs, or CROs may engage in misconduct or other improper activities, including noncompliance

with regulatory standards and requirements, which could have a material adverse effect on our business.

We are exposed to the risk of employee fraud

or other misconduct.

Misconduct by employees, independent contractors, consultants, commercial partners, principal investigators,

CMOs, or CROs could include intentional, reckless, negligent, or unintentional failures to comply with FDA regulations, comply

with applicable fraud and abuse laws, provide accurate information to the FDA, properly calculate pricing information required

by federal programs, report financial information or data accurately or disclose unauthorized activities to us.

This misconduct

could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could

result in regulatory sanctions and serious harm to our reputation.

It is not always possible to identify and deter this type of

misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged

risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be

in compliance with such laws or regulations.

Moreover, it is possible for a whistleblower to pursue a False Claims Act case against

us even if the government considers the claim unmeritorious and declines to intervene, which could require us to incur costs defending

against such a claim.

If any such actions are instituted against us, and we are not successful in defending ourselves or asserting

our rights, those actions could have a significant impact on our business, financial condition, results of operations, stock price

and prospects, including the imposition of significant fines or other sanctions.

Violations of or liabilities under environmental, health

and safety laws and regulations could subject us to fines, penalties or other costs that could have a material adverse effect on

the success of our business.

We are subject to numerous environmental,

health and safety laws and regulations, including those governing laboratory procedures, the handling, use, storage, treatment

and disposal of hazardous materials and wastes and the cleanup of contaminated sites.

Our operations involve the use of hazardous

and flammable materials, including chemicals and biological and radioactive materials.

Our operations also produce hazardous waste

We would incur substantial costs as a result of violations of or liabilities under environmental requirements in connection

with our operations or property, including fines, penalties and other sanctions, investigation and cleanup costs and third-party

Although we generally contract with third parties for the disposal of hazardous materials and wastes from our operations,

we cannot eliminate the risk of contamination or injury from these materials.

In the event of contamination or injury resulting

from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.

We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers compensation insurance to cover costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities.

We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

Our internal computer systems, or those of our third party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our development programs.

Our internal computer systems, and those of our CROs, CMOs, information technology suppliers and other contractors and consultants are vulnerable to damage from computer viruses, cyber-attacks and other unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures.

If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs.

For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.

To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of any of our product candidates could be delayed.

Although we maintain workers’

insurance to cover costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials,

this insurance may not provide adequate coverage against potential liabilities.

We do not maintain insurance for environmental

liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous

Our internal computer systems, or those of our third-party

CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of

our development programs.

Our internal computer systems, and those

of our CROs, CMOs, information technology suppliers and other contractors and consultants are vulnerable to damage from computer

viruses, cyber-attacks and other unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures.

If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development

For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays

in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.

To the extent that any

disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of

personal, confidential or proprietary information, we could incur liability and the further development of any of our product candidates

could be delayed.

Risks related to our operations

We will need to expand the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.

As of December 31, 2019, we had 104 fulltime employees, including 89 employees engaged in research and development.

As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial and other personnel.

Our financial condition and results

of operations could be adversely affected by the recent novel coronavirus disease-2019, or COVID-19, outbreak.

In December 2019, a novel strain of

coronavirus, now referred to as COVID-19, surfaced in Wuhan, China.

The virus continues to spread globally, including the United

States, the United Kingdom and other countries in which we conduct clinical trials, and has been declared a pandemic by the World

Health Organization.

The impact of this pandemic has been and will likely continue to be extensive in many aspects of society,

which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses

and capital markets around the world.

In an effort to halt the outbreak of COVID-19, many countries, including the United States,

the United Kingdom and certain other countries in which we conduct clinical trials, placed significant restrictions on travel and

business operations or issued shelter-in-place orders.

These restrictions and orders continue to remain in effect to varying degrees,

the effect of which required, and in some instances, continue to require, certain of our employees and clinical trial staff to

work remotely and avoid unnecessary travel.

While these restrictions and orders have eased in certain geographies in which we operate,

the effect of these restrictions and orders has impacted the pace of enrollment in our clinical trials, and if they continue, may

affect our results and operations.

The COVID-19 pandemic is affecting the United

States and global economies and has affected and may continue to affect our operations and those of third parties on which we rely,

including by causing disruptions in our raw material and anti-PD-1 supply, the manufacturing of our product candidates, the commercialization

of our product candidates and the conduct of current and future clinical trials.

In addition, the COVID-19 pandemic has affected

and may continue to affect the operations of the FDA and comparable foreign regulatory authorities, which could result in delays

of reviews and approvals, including with respect to RP1 and our other product candidates.

The evolving COVID-19 pandemic has also

directly or indirectly impacted and is likely to continue to impact the pace of enrollment in our clinical trials as patients may

avoid or may not be able to travel to healthcare facilities and physicians' offices unless due to a health emergency and clinical

trial staff may no longer be able to get to the clinic.

Such facilities and offices have and may continue to be required to focus

limited resources on non-clinical trial matters, including treatment of COVID-19 patients, and may not be available, in whole or

in part, for clinical trial services.

For example, our clinical trial of RP1 in solid organ transplant patients with CSCC, representing

a highly immunocompromised patient populations, has been slower than expected.

In addition, employee disruptions and remote working

environments related to the COVID-19 pandemic and the federal, state and local responses to such virus, could materially impact

the efficiency and pace with which we work and develop our product candidates.

The COVID-19 pandemic and the government

and public health response continues to rapidly evolve.

In light of the COVID-19 pandemic, the FDA has issued a number of new guidance

Specifically, as a result of the potential effect of the COVID-19 pandemic on many clinical trial programs in the United

States and globally, the FDA issued guidance concerning potential impacts on clinical trial programs, changes that may be necessary

to such programs if they proceed, considerations regarding trial suspensions and discontinuations, the potential need to consult

with or make submissions to relevant ethics committees, IRBs, and the FDA, the use of alternative drug delivery methods, and

considerations with respect the outbreak's impacts on endpoints, data collection, study procedures, and analysis.

Additionally,

in March 2020, the U.S.

Congress passed the Coronavirus Aid, Relief, and Economic Security Act, which includes a number of

provisions that are applicable to the pharmaceutical industry, and further acts, laws or regulations may be enacted or implemented

in the future.

While the potential economic impact brought

by, and the duration and severity of, the COVID-19 pandemic are difficult to assess or predict, the impact of the COVID-19 pandemic

on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term

Additionally, the stock market has been unusually volatile during the COVID-19 outbreak and such volatility may continue.

To date, during certain periods of the COVID-19 pandemic, our stock price fluctuated significantly, and such fluctuation may continue

The ultimate impact of the COVID-19 pandemic on our business will largely depend on future developments, which are highly

uncertain, cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic,

travel restrictions and social distancing in the United States and other countries, business closures or business disruptions,

the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and

other countries to contain and treat the disease.

We do not yet know the full extent of the

delays or impacts on our business, financing or clinical trial activities, healthcare systems or the global economy as a whole.

However, these effects could have a material impact on our liquidity, capital resources, operations and business and those of the

third parties on which we rely.

To the extent to COVID-19 pandemic materially impacts our business and financial results, it may

also have the effect of significantly heightening many of the other risk described in this "Risk Factors"

We will need to expand the size of our organization, and

we may experience difficulties in managing this growth, which could disrupt our operations.

As our development and commercialization

plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial and other personnel.

Future growth would impose significant added responsibilities on members of management, including:

● identifying, recruiting, integrating, maintaining and motivating additional employees;

· managing our internal development efforts effectively, including the clinical, FDA and comparable foreign regulatory review process for our product candidates, while complying with our contractual obligations to contractors and other third parties;

● managing our internal development efforts effectively, including the clinical, FDA and comparable foreign regulatory review

process for our product candidates, while complying with our contractual obligations to contractors and other third parties;

● strengthening our operational, financial and management controls, reporting systems and procedures.

Our future financial performance and our ability to commercialize RP1 and our other product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.

We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services.

The services include substantially all aspects of clinical trial management and manufacturing, as well as support for our financial reporting and accounting functions.

We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements.

In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed

or terminated, we may not comply with our financial reporting and accounting obligations on a timely basis and we may not be able to obtain marketing approval of RP1 and our other product candidates or otherwise advance our business.

We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.

If we are not able to effectively expand our organization by hiring qualified new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize RP1 and our other product candidates and, accordingly, may not achieve our research, development and commercialization goals.

We are highly dependent on our key personnel, including Robert Coffin, Ph.D., our President and Chief Research & Development Officer;

Our future financial performance and our

ability to commercialize RP1 and our other product candidates will depend, in part, on our ability to effectively manage any future

growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in

order to devote a substantial amount of time to managing these growth activities.

We currently rely, and for the foreseeable

future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain

The services include substantially all aspects of clinical trial management and manufacturing, as well as support for

our financial reporting and accounting functions.

We cannot assure you that the services of independent organizations, advisors

and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements.

In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided

by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, we may not comply with

our financial reporting and accounting obligations on a timely basis and we may not be able to obtain marketing approval of RP1

and our other product candidates or otherwise advance our business.

We cannot assure you that we will be able to manage our existing

consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.

If we are not able to effectively expand

our organization by hiring qualified new employees and expanding our groups of consultants and contractors, we may not be able

to successfully implement the tasks necessary to further develop and commercialize RP1 and our other product candidates and, accordingly,

may not achieve our research, development and commercialization goals.

We are highly dependent on our key personnel, including

Philip Astley-Sparke, our Chief Executive Officer;

Robert Coffin, Ph.D., our President and Chief Research & Development

and Colin Love, Ph.D., our Chief Operating Officer.

If we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel.

We are highly dependent on our management and particularly on the services of our founders, as well as our other scientific, manufacturing, quality and medical personnel.

Robert Coffin, Ph.D., our President and Chief Research & Development Officer, Philip Astley-Sparke, our Chief Executive Officer, and Colin Love, Ph.D., our Chief Operating Officer, were the founder and senior management team of BioVex Group, Inc., or BioVex, where they invented and developed T-VEC, the only oncolytic immunotherapy to receive FDA approval.

If we are not successful in attracting, motivating and retaining highly

qualified personnel, we may not be able to successfully implement our business strategy.

Our ability to compete in the highly competitive

biotechnology and pharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial,

scientific and medical personnel.

We are highly dependent on our management and particularly on the services of our founders, as

well as our other scientific, manufacturing, quality and medical personnel.

Philip Astley-Sparke, our Chief Executive Officer,

Robert Coffin, Ph.D., our President and Chief Research & Development Officer, and Colin Love, Ph.D., our Chief Operating

Officer, were the founder and senior management team of BioVex Group, Inc., or BioVex, where they invented and developed T-Vec,

the only oncolytic immunotherapy to receive FDA approval.

BioVex was acquired by Amgen Inc., or Amgen, in 2011.

We believe that their drug discovery and development experience, and overall biopharmaceutical company management experience, would be difficult to replace.

The loss of the services of our key personnel and any of our other executive officers, key employees, and scientific and medical advisors, and our inability to find suitable replacements, could result in delays in product development and harm our business.

Furthermore, the historical results, past performance and/or acquisitions of companies with which our founders were affiliated, including BioVex, do not necessarily predict or guarantee similar results for our company.

We conduct our operations at our facilities near Boston, Massachusetts and near Oxford, England, each of which are in regions that are home to many other biopharmaceutical companies and many academic and research institutions.

Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.

that their drug discovery and development experience, and overall biopharmaceutical company management experience, would be difficult

The loss of the services of our key personnel and any of our other executive officers, key employees, and scientific

and medical advisors, and our inability to find suitable replacements, could result in delays in product development and harm our

Furthermore, the historical results, past performance and/or acquisitions of companies with which our founders were affiliated,

including BioVex, do not necessarily predict or guarantee similar results for our company.

We conduct our operations at our facilities

near Boston, Massachusetts and near Oxford, England, each of which are in regions that are home to many other biopharmaceutical

companies and many academic and research institutions.

Competition for skilled personnel is intense

and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms

We expect that we will need to recruit talent from outside of these regions, and doing so may be costly and difficult.

To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock option grants that vest over time.

The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies.

Although we have employment agreements with our key employees, these employment agreements generally provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice.

We do not maintain key man insurance policies on the lives of any of these individuals or the lives of any of our other employees.

We have identified material weaknesses in our internal control over financial reporting.

If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.

In connection with the audits of our consolidated financial statements as of and for the years ended March 31, 2019, 2018 and 2017, we identified material weaknesses in our internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

The material weaknesses we identified were as follows:

To induce valuable employees to remain at

our company, in addition to salary and cash incentives, we have provided stock option grants that vest over time.

employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond

our control, and may at any time be insufficient to counteract more lucrative offers from other companies.

Although we have employment

agreements with our key employees, these employment agreements generally provide for at-will employment, which means that any of

our employees could leave our employment at any time, with or without notice.

We do not maintain “key man”

policies on the lives of any of these individuals or the lives of any of our other employees.

We have identified material weaknesses in our internal

control over financial reporting.

If we are unable to remediate these material weaknesses, or if we identify additional material

weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately

or timely report our financial condition or results of operations, which may adversely affect our business.

In connection with the audits of our consolidated

financial statements as of and for the years ended March 31, 2020, 2019 or 2018, we identified material weaknesses in our

internal control over financial reporting.

However, these material weaknesses did not result in a restatement for the years ended

March 31, 2020, 2019 or 2018.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over

financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial

statements will not be prevented or detected on a timely basis.

If we are unable to remediate these material weaknesses, or if

we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls,

we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect

investor confidence in us and, as a result, our stock price and ability to access the capital markets in the future.

The material weaknesses we identified were

● We did not design or maintain an effective control environment commensurate with our financial reporting requirements.

We lacked a sufficient number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately.

Additionally, the

limited personnel resulted in our inability to consistently establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives, as demonstrated by, among other things, our insufficient segregation of duties in our accounting function.

This material weakness further contributed to the material weakness below.

· We did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions, including accounting for preferred stock, stock-based compensation, warrant liabilities and leases.

Each of these control deficiencies could result in a misstatement of our accounts or disclosures that would result in a material misstatement of our annual or interim consolidated financial statements that would not be prevented or detected, and accordingly, we determined that these control deficiencies constitute material weaknesses.

These material weaknesses also resulted in adjustments to preferred stock, stock compensation expense, warrant liability and deferred rent in our consolidated financial statements as of and for the year ended March 31, 2017, which were recorded prior to their issuance.

Prior to the completion of our IPO, we were a private company with limited accounting personnel to adequately execute our accounting processes and other supervisory resources with which to address our internal control over financial reporting.

We have implemented, and continue to implement, measures designed to improve our internal control over financial reporting and remediate the control deficiencies that led to these material weaknesses.

To date, we have hired Jean Franchi, our first Chief Financial Officer, and additional finance and accounting personnel and have engaged a third party consulting firm to assist us in the design and documentation of appropriate controls.

We are continuing these efforts in order to design and implement our financial control environment, including the establishment of controls to account for and disclose complex transactions.

We cannot assure you that the measures we have taken to date, and actions we intend to take in the future, will be sufficient to remediate the control deficiencies that led to these material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses.

In addition, neither our management nor an independent registered public accounting firm has performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act because no such evaluation has been required.

Had we or our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified.

If we are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, potentially resulting in restatements of our financial statements, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports and applicable Nasdaq listing requirements, investors may lose confidence in our financial reporting, and our share price may decline as a result.

If we fail to establish and maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired.

We are required to maintain internal controls over financial reporting.

Commencing with our fiscal year ending March 31, 2020, we must perform system and process design evaluation and testing of the effectiveness of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act.

This will require that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts.

Prior to our IPO, we were not required to test our internal controls within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner.

If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, if our independent registered public accounting firm determines that we continue to have a material weakness or significant deficiency in our internal control over financial reporting, or if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements.

If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC, Nasdaq or other regulatory authorities.

We believe that any internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our consolidated financial statements.

Our internal control over financial reporting will not prevent or detect all errors and all fraud.

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.

These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple error or mistake.

Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls.

Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

Our disclosure controls and procedures were not effective as of March 31, 2019, and in any event may not prevent or detect all errors or acts of fraud.

We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.

Based on the evaluation of our disclosure controls and procedures as of December 31, 2019, we concluded that, as of December 2019, our disclosure controls and procedures were not effective at the reasonable assurance level as a result of the material weaknesses discussed above.

Notwithstanding these material weaknesses, our management has concluded that the financial statements included elsewhere in this Quarterly Report present fairly, in all material respects, our financial position, results of operations and cash flows in conformity with generally accepted accounting principles.

We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple error or mistake.

Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls.

Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.

We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses.

a sufficient number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately

analyze, record and disclose accounting matters timely and accurately.

Additionally, the limited personnel resulted in our inability

to consistently establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives, as demonstrated

by, among other things, our insufficient segregation of duties in our accounting function.

This material weakness further contributed

to the material weakness below.

● We did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex

transactions, including accounting for preferred stock, stock-based compensation, warrant liabilities and leases.

Each of these control deficiencies could

result in a misstatement of our accounts or disclosures that would result in a material misstatement of our annual or interim consolidated

financial statements that would not be prevented or detected, and accordingly, we determined that these control deficiencies constitute

material weaknesses.

These material weaknesses also resulted

in adjustments to preferred stock, stock compensation expense, warrant liability and deferred rent in our consolidated financial

statements as of and for the year ended March 31, 2017, which were recorded prior to their issuance.

Prior to the completion of our IPO, we were

a private company with limited accounting personnel to adequately execute our accounting processes and other supervisory resources

with which to address our internal control over financial reporting.

We have implemented, and continue to implement, measures designed

to improve our internal control over financial reporting and remediate the control deficiencies that led to these material weaknesses.

In December 2019 we hired Jean Franchi, our first Chief Financial Officer, and we continue to hire additional finance and

accounting personnel.

We have also engaged a third-party consulting firm to assist us in the design and documentation of appropriate

We are continuing these efforts in order to design and implement our financial control environment, including the establishment

of controls to account for and disclose complex transactions.

We cannot assure you that the measures we

have taken to date, and actions we intend to take in the future, will be sufficient to remediate the control deficiencies that

led to these material weaknesses in our internal control over financial reporting or that they will prevent or avoid potential

future material weaknesses.

In addition, our independent registered public accounting firm has not performed an evaluation of our

internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act because no such evaluation

has been required.

Had our independent registered public accounting firm performed an evaluation of our internal control over financial

reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified.

If we are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial

reporting, or identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely

affected, potentially resulting in restatements of our financial statements, we may be unable to maintain compliance with securities

law requirements regarding timely filing of periodic reports and applicable Nasdaq listing requirements, investors may lose confidence

in our financial reporting, and our share price may decline as a result.

If we fail to establish and maintain proper and effective

internal control over financial reporting our ability to produce accurate and timely financial statements could be impaired.

We are required to maintain internal control

over financial reporting.

We must perform system and process design evaluation and testing of the effectiveness of our internal

controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting,

as required by Section 404 of the Sarbanes-Oxley Act.

We continue to be engaged in a process to document and evaluate our

internal control over financial reporting, which is both costly and challenging.

In this regard, we will need to continue to incur

substantial professional fees and internal costs for our accounting and finance functions, expend significant management efforts,

continue to implement plans developed to address areas that we have identified as requiring improvement, validate through testing

that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over

financial reporting.

If we are not able to comply with the requirements

of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal

controls over financial reporting, we may not be able to produce timely and accurate financial statements.

If that were to happen,

our investors could lose confidence in our reported financial information, the market price of our stock could decline and we could

be subject to sanctions or investigations by the SEC, Nasdaq or other regulatory authorities.

We believe that any internal controls and

procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives

of the control system are met.

We may discover weaknesses in our system of internal financial and accounting controls and procedures

that could result in a material misstatement of our consolidated financial statements.

Our internal control over financial reporting

will not prevent or detect all errors and all fraud.

Because of the inherent limitations in all control systems, no evaluation

of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and

instances of fraud will be detected.

These inherent limitations include the realities

that judgments in decision making can be faulty, and that breakdowns can occur because of simple error or mistake.

Additionally,

controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override

of the controls.

Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may

occur and not be detected.

Our disclosure controls and procedures were not effective

as of June 30, 2020, and in any event may not prevent or detect all errors or acts of fraud.

We must design our disclosure controls

and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is

accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods

specified in the rules and forms of the SEC.

Based on the evaluation of our disclosure controls and procedures as of

June 30, 2020, we concluded that, as of June 30, 2020, our disclosure controls and procedures were not

effective at the reasonable assurance level as a result of the material weaknesses discussed above.

Notwithstanding these

material weaknesses, our management has concluded that the financial statements included elsewhere in this Quarterly Report

present fairly, in all material respects, our financial position, results of operations and cash flows in conformity with

generally accepted accounting principles.

We believe that any disclosure controls and procedures or internal controls and

procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the

objectives of the control system are met.

These inherent limitations include the realities that judgments in decision making

can be faulty, and that breakdowns can occur because of simple error or mistake.

Additionally, controls can be circumvented

by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls.

Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not

If we engage in future acquisitions or strategic partnerships,

this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and

subject us to other risks.

We may evaluate various acquisitions and

strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or

Any potential acquisition or strategic partnership may entail numerous risks, including:

2 unchanged sentences

● the issuance of our equity securities;

· assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;

· the diversion of our managements attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;

● assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with

integrating new personnel;

● the diversion of our management’s attention from our existing product programs and initiatives in pursuing such a strategic

merger or acquisition;

● retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;

· risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance status, and their existing products or product candidates and marketing approvals;

· our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.

In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large onetime expenses and acquire intangible assets that could result in significant future amortization expense or intangible asset impairment charges.

Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.

Any of the foregoing may materially harm our business, financial condition, results of operations, stock price and prospects.

Unfavorable market and economic conditions may have serious adverse consequences on our business, financial condition, results of operations, stock price and prospects.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets.

The most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets.

A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all.

● risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their

regulatory compliance status, and their existing products or product candidates and marketing approvals;

● our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking

the acquisition or even to offset the associated acquisition and maintenance costs.

In addition, if we undertake acquisitions,

we may issue dilutive securities, assume or incur debt obligations, incur large onetime expenses and acquire intangible assets

that could result in significant future amortization expense or intangible asset impairment charges.

Moreover, we may not be able

to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology

or products that may be important to the development of our business.

Any of the foregoing may materially harm our business, financial

condition, results of operations, stock price and prospects.

Unfavorable market and economic conditions may have serious

adverse consequences on our business, financial condition, results of operations, stock price and prospects.

Our results of operations could be adversely

affected by general conditions in the global economy and in the global financial markets.

The most recent global financial crisis

caused extreme volatility and disruptions in the capital and credit markets.

A severe or prolonged economic downturn could result

in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms,

A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption.

Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the economic climate and financial market conditions could adversely impact our business.

At December 31, 2019, we had $180.9 million of cash and cash equivalents and short term investments.

Although we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents or short term investments since that date, we cannot assure you that deterioration of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or short term investments, or our ability to meet our financing objectives.

Furthermore, our stock price may decline due, in part, to the volatility of the stock market and general economic downturns.

Exchange rate fluctuations may materially affect our results of operations and financial conditions.

Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the U.S.

dollar and the British pound and the euro, may adversely affect us.

Although we are based in the United States, we have significant research and development operations in the United Kingdom, and source third party manufacturing, consulting and other services in the United Kingdom and the European Union.

As a result, our business and the price of our common stock may be affected by fluctuations in foreign exchange rates, which may have a significant impact on our results of operations and cash flows from period to period.

Currently, we do not have any exchange rate hedging arrangements in place.

Any of the foregoing

could harm our business and we cannot anticipate all of the ways in which the economic climate and financial market conditions

could adversely impact our business.

Global financial markets have been experiencing

extreme disruption in recent months, including, among other things, extreme volatility in securities prices.

We are unable to predict

the likely duration and severity of the current disruptions in financial markets and adverse economic conditions throughout the

These economic developments affect businesses such as ours and those of third parties on which we rely in a number of ways

that could result in unfavorable consequences to us.

Current economic conditions or a deepening economic downturn in the United

States and elsewhere may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity.

At June 30, 2020, we had $261.8 million

of cash and cash equivalents and short-term investments.

Although we are not aware of any downgrades, material losses, or other

significant deterioration in the fair value of our cash equivalents or short-term investments since that date, we cannot assure

you that deterioration of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents

or short-term investments, or our ability to meet our financing objectives.

Furthermore, our stock price may decline due, in part,

to the volatility of the stock market and general economic downturns.

Exchange rate fluctuations may materially affect our results

of operations and financial conditions.

Owing to the international scope of our

operations, fluctuations in exchange rates, particularly between the U.S.

dollar and the British pound and the euro, may adversely

Although we are based in the United States, we have significant research and development operations in the United Kingdom,

and source third-party manufacturing, consulting and other services in the United Kingdom and the European Union.

our business and the price of our common stock may be affected by fluctuations in foreign exchange rates, which may have a significant

impact on our results of operations and cash flows from period to period.

Currently, we do not have any exchange rate hedging arrangements

Risks related to our common stock

An active trading market for our common stock may not be sustained.

Our common stock began trading on the Nasdaq Global Select Market on July 19, 2018.

Given the limited trading history of our common stock, there is a risk that an active trading market for shares of our common stock may not be sustained.

In the absence of an active trading market for shares of our common stock, our stockholders may not be able to sell their common stock at or above the price at which such stockholder acquired our common stock or at the time that they would like to sell.

The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.

Our stock price has been and is likely to be volatile.

The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies.

As a result of this volatility, you may not be able to sell your common stock at or above the price at which it was acquired.

The market price for our common stock may be influenced by many factors, including:

An active trading market for our common stock may not

be sustained.

Our common stock began trading on the Nasdaq

Global Select Market on July 20, 2018.

Given the limited trading history of our common stock, there is a risk that an active

trading market for shares of our common stock may not be sustained.

In the absence of an active trading market for shares of our

common stock, our stockholders may not be able to sell their common stock at or above the price at which such stockholder acquired

our common stock or at the time that they would like to sell.

The price of our common stock may be volatile and fluctuate

substantially, which could result in substantial losses for purchasers of our common stock.

Our stock price has been and is likely to

The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme

volatility that has often been unrelated to the operating performance of particular companies.

As a result of this volatility,

you may not be able to sell your common stock at or above the price at which it was acquired.

The market price for our common stock

may be influenced by many factors, including:

● the success of competitive products or technologies;

5 unchanged sentences

● the results of our efforts to discover, develop, acquire or in-license additional product candidates or drugs;

· actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

● actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities

● variations in our financial results or those of companies that are perceived to be similar to us;

2 unchanged sentences

● general economic, industry and market conditions;

· the other factors described in this Risk factors section.

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.

Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results.

From time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue.

Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under current and any potential future license and collaboration agreements and sales of our products, if approved.

These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.

In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employees requisite service period.

As the variables that we use as a basis for valuing these awards change over time, including, our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.

Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:

· timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which will change from time to time;

· the total expenses we incur in connection with equipping, and operating our manufacturing facility and the actual timing of the facility becoming fully operational;

● political and economic instability, including the impact of COVID-19, the possibility of an economic recession, international

hostilities, acts of terrorism and governmental restrictions, inflation, trade relationships and military and political alliances;

● the other factors described in this “Risk factors”

Our operating results may fluctuate significantly, which

makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our

Our quarterly and annual operating results

may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results.

time, we may enter into license or collaboration agreements with other companies that include development funding and significant

upfront and milestone payments and/or royalties, which may become an important source of our revenue.

Accordingly, our revenue

may depend on development funding and the achievement of development and clinical milestones under current and any potential future

license and collaboration agreements and sales of our products, if approved.

These upfront and milestone payments may vary significantly

from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the

In addition, we measure compensation cost

for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by

our board of directors, and recognize the cost as an expense over the employee’s requisite service period.

As the variables

that we use as a basis for valuing these awards change over time, including, our underlying stock price and stock price volatility,

the magnitude of the expense that we must recognize may vary significantly.

Furthermore, our operating results may fluctuate

due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:

● timing and cost of, and level of investment in, research and development activities relating to our current and any future

product candidates, which will change from time to time;

● the total expenses we incur in connection with equipping and operating our manufacturing facility;

● our ability to enroll patients in clinical trials and the timing of enrollment;

· the cost of manufacturing our current and any future product candidates, which may vary depending on the FDAs and comparable foreign regulatory authorities guidelines and requirements, the quantity of production and the terms of any agreements with manufacturers;

● the cost of manufacturing our current and any future product candidates, which may vary depending on the FDA’s and comparable

foreign regulatory authorities’

guidelines and requirements, the quantity of production and the terms of any agreements with

manufacturers;

● expenditures that we will or may incur to acquire or develop additional product candidates and technologies;

● the timing and outcomes of clinical and preclinical studies for RP1 and our other product candidates or competing product candidates;

· competition from existing and potential future products that compete with RP1 and our other product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;

● competition from existing and potential future products that compete with RP1 and our other product candidates, and changes

in the competitive landscape of our industry, including consolidation among our competitors or partners;

● any delays in regulatory review or approval of RP1 or our other product candidates;

· the level of demand for RP1 and our other product candidates, if approved, which may fluctuate significantly and be difficult to predict;

· the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with RP1 and our other product candidates;

· our ability to commercialize RP1 and our other product candidates, if approved, inside and outside of the United States, either independently or working with third parties;

● the level of demand for RP1 and our other product candidates, if approved, which may fluctuate significantly and be difficult

● the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing

and potential future products that compete with RP1 and our other product candidates;

● our ability to commercialize RP1 and our other product candidates, if approved, inside and outside of the United States, either

independently or working with third parties;

● the success of and our ability to establish and maintain collaborations, licensing or other arrangements;

1 unchanged sentence

● potential unforeseen business disruptions that increase our costs or expenses;

● political and economic instability, including the impact of the COVID-19 coronavirus, the possibility of an economic recession,

international hostilities, acts of terrorism and governmental restrictions, inflation, trade relationships and military and political

● future accounting pronouncements or changes in our accounting policies;

● the changing and volatile global economic environment.

These factors could result in large fluctuations and unpredictability in our quarterly and annual operating results.

As a result, comparing our operating results on a period-to-period basis may not be meaningful.

These factors could result in large fluctuations

and unpredictability in our quarterly and annual operating results.

As a result, comparing our operating results on a period-to-period

basis may not be meaningful.

Investors should not rely on our past results as an indication of our future performance.

This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period.

If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially.

Such a stock price decline could occur even when we have met any previously publicly stated revenue and/or earnings guidance we may provide.

We have broad discretion in how we use our cash, cash equivalents and investments, and may not use these resources effectively, which could affect our results of operations and cause our stock price to decline.

Our management has considerable discretion in the application of our cash, cash equivalents and investments.

We intend to use our resources to fund our preclinical and clinical development programs as well as for general corporate purposes, including working capital requirements and other operating expenses.

As a result, investors will be relying upon managements judgment with only limited information about our specific intentions for the use of our resources.

We may use our resources for purposes that do not yield a significant return or any return at all for our stockholders.

In addition, pending their use, we may invest our cash, cash equivalents and investments in a manner that does not produce income or that loses value.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.

Any return to stockholders will therefore be limited to the appreciation of their stock, which may never occur, as the only way to realize any return on their investment.

Our executive officers, directors, and stockholders and their affiliates who beneficially own more than 5% of our common stock exercise significant influence over our company, which limits your ability to influence corporate matters and could delay or prevent a change in corporate control.

Based on the number of shares outstanding as of December 31, 2019, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned a significant portion of our voting stock and, accordingly, these stockholders will continue to have significant influence over matters requiring stockholder approval.

For example, these stockholders will continue to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction.

This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

Conflicts of interest may arise because some members of our board of directors are representatives of our principal stockholders.

Certain of our principal stockholders or their affiliates are venture capital funds or other investment vehicles that could invest in entities that directly or indirectly compete with us.

As a result of these relationships, when conflicts arise between the interests of the principal stockholders or their affiliates and the interests of other stockholders, members of our board of directors that are representatives of the principal stockholders may not be disinterested.

Neither the principal stockholders nor the representatives of the principal stockholders on our board of directors, by the terms of our amended and restated certificate of incorporation, are required to offer us any transaction opportunity of which they become aware and could take any such opportunity for themselves or offer it to their other affiliates, unless such opportunity is expressly offered to them solely in their capacity as members of our board of directors.

Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.

If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the expiration of contractual or legal restrictions on resale lapse, the market price of our common stock could decline.

These sales may make it more difficult for us to sell equity or equity related securities in the future at a time and price that we deem appropriate, or to use equity as consideration for future acquisition.

In addition, approximately 10.1 million shares of common stock that are either subject to outstanding options, reserved for future issuance under our equity incentive plans or subject to outstanding warrants are eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act.

If these additional

shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.

Certain holders of shares of our common stock, or their permitted transferees, are entitled to rights with respect to the registration under the Securities Act of approximately 19.2 million shares of our common stock pursuant to the amended and restated investors rights agreement by and among us and certain of our stockholders.

Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates.

Any sales of securities by these stockholders could have a material adverse effect on the market price of our common stock.

We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.

As a public company, we incur significant legal, accounting and other expenses.

We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition.

In addition, the Sarbanes-Oxley Act, and related SEC and Nasdaq rules impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices.

This variability and unpredictability could

also result in our failing to meet the expectations of industry or financial analysts or investors for any period.

If our revenue

or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market,

or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock

could decline substantially.

Such a stock price decline could occur even when we have met any previously publicly stated revenue

and/or earnings guidance we may provide.

We have broad discretion in how we use our cash, cash

equivalents and investments, and may not use these resources effectively, which could affect our results of operations and cause

our stock price to decline.

Our management has considerable discretion

in the application of our cash, cash equivalents and investments.

We intend to use our resources to fund our preclinical and clinical

development programs as well as for general corporate purposes, including working capital requirements and other operating expenses.

As a result, investors will be relying upon management’s judgment with only limited information about our specific intentions

for the use of our resources.

We may use our resources for purposes that do not yield a significant return or any return at all

for our stockholders.

In addition, pending their use, we may invest our cash, cash equivalents and investments in a manner that

does not produce income or that loses value.

We do not intend to pay dividends on our common stock

so any returns will be limited to the value of our stock.

We currently anticipate that we will retain

future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash

dividends for the foreseeable future.

Any return to stockholders will therefore be limited to the appreciation of their stock,

which may never occur, as the only way to realize any return on their investment.

Our executive officers, directors, and stockholders and

their affiliates who beneficially own more than 5% of our common stock exercise significant influence over our company, which limits

your ability to influence corporate matters and could delay or prevent a change in corporate control.

Based on the number of shares outstanding

as of June 30, 2020, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates

beneficially owned a significant portion of our voting stock and, accordingly, these stockholders will continue to have significant

influence over matters requiring stockholder approval.

For example, these stockholders will continue to significantly influence

elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate

This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel

are in your best interest as one of our stockholders.

Conflicts of interest may arise because some members of

our board of directors are representatives of our principal stockholders.

Certain of our principal stockholders or

their affiliates are venture capital funds or other investment vehicles that could invest in entities that directly or indirectly

compete with us.

As a result of these relationships, when conflicts arise between the interests of the principal stockholders or

their affiliates and the interests of other stockholders, members of our board of directors that are representatives of the principal

stockholders may not be disinterested.

Neither the principal stockholders nor the representatives of the principal stockholders

on our board of directors, by the terms of our amended and restated certificate of incorporation, are required to offer us any

transaction opportunity of which they become aware and could take any such opportunity for themselves or offer it to their other

affiliates, unless such opportunity is expressly offered to them solely in their capacity as members of our board of directors.

Sales of a substantial number of shares of our common

stock in the public market could cause our stock price to fall.

If our existing stockholders sell, or indicate

an intention to sell, substantial amounts of our common stock in the public market after the expiration of contractual or legal

restrictions on resale lapse, the market price of our common stock could decline.

These sales may make it more difficult for us

to sell equity or equity related securities in the future at a time and price that we deem appropriate, or to use equity as consideration

for future acquisition.

In addition, approximately 13.7 million

shares of common stock that are either subject to outstanding options, reserved for future issuance under our equity incentive

plans or subject to outstanding warrants are eligible for sale in the public market to the extent permitted by the provisions of

various vesting schedules and Rule 144 and Rule 701 under the Securities Act.

If these additional shares of common stock

are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.

Certain holders of shares of our common

stock, or their permitted transferees, are entitled to rights with respect to the registration under the Securities Act of shares

of our common stock pursuant to the amended and restated investors' rights agreement by and among us and certain of our stockholders.

Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under

the Securities Act, except for shares purchased by affiliates.

Any sales of securities by these stockholders could have a material

adverse effect on the market price of our common stock.

We may sell up to $30.0 million of shares

of our common stock in “at-the-market”

offerings pursuant to the sales agreement entered into with SVB Leerink LLC

on August 8, 2019 and as amended on June 8, 2020.

The sale of a substantial number of shares of our common stock pursuant

to the sales agreement, or anticipation of such sales, could cause the trading price of our common stock to decline or make it

more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise

In addition, issuances of any shares of our common stock sold pursuant to the sales agreement will have a dilutive effect

on our existing stockholders.

We incur significant costs as a result of operating as

a public company, and our management is required to devote substantial time to compliance initiatives.

As a public company, we incur significant

legal, accounting and other expenses.

We are subject to the reporting requirements of the Exchange Act, which requires, among other

things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition.

addition, the Sarbanes-Oxley Act and related SEC and Nasdaq rules impose significant requirements on public companies, including

requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices.

Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted.

There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as say on pay and proxy access.

Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of our IPO.

We intend to take advantage of this new legislation, but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses.

Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.

The rules and regulations applicable to public companies have substantially increased our legal and financial compliance costs and have made some activities more time consuming and costly.

If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business.

For example, these rules and regulations have made it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage.

The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.

The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business.

If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline.

If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which, in turn, could cause our stock price to decline.

Antitakeover provisions in our charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of our company or a change in our management.

These provisions include a classified board of directors and the ability of our board of directors to issue preferred stock without stockholder approval.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with our company.

Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board of directors were considered beneficial by some stockholders.

In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for our stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.

We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the

SEC to adopt additional rules and regulations in these areas such as “say on pay”

and proxy access.

Emerging growth

companies are permitted to implement many of these requirements over a longer period and up to five years from the pricing of our

We intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public

companies that are not emerging growth companies, but cannot guarantee that we will not be required to implement these requirements

sooner than budgeted or planned and thereby incur unexpected expenses.

Stockholder activism, the current political environment

and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure

obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot

currently anticipate.

The rules and regulations applicable

to public companies have substantially increased our legal and financial compliance costs and have made some activities more time

consuming and costly.

If these requirements divert the attention of our management and personnel from other business concerns,

they could have a material adverse effect on our business, financial condition, results of operations, stock price and prospects.

The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of

our business.

For example, these rules and regulations have made it more difficult and more expensive for us to obtain director

and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage.

impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board

of directors, our board committees or as executive officers.

If securities analysts do not publish research or reports

about our business or if they publish negative evaluations of our stock, the price of our stock could decline.

The trading market for our common stock

relies, in part, on the research and reports that industry or financial analysts publish about us or our business.

If one or more

of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline.

more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which, in turn, could cause

our stock price to decline.

Antitakeover provisions in our charter documents and under

Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent

attempts by our stockholders to replace or remove our current management.

Provisions in our amended and restated certificate

of incorporation and amended and restated bylaws may delay or prevent an acquisition of our company or a change in our management.

These provisions include a classified board of directors and the ability of our board of directors to issue preferred stock without

stockholder approval.

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203

of the Delaware General Corporation Law, or DGCL, which limits the ability of stockholders owning in excess of 15% of our outstanding

voting stock to merge or combine with our company.

Although we believe these provisions collectively provide for an opportunity

to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would

apply even if an offer rejected by our board of directors were considered beneficial by some stockholders.

In addition, these provisions

may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult

for our stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.

We are an emerging growth company and a smaller reporting

company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies or smaller reporting

companies will make our common stock less attractive to investors.

We are an emerging growth company.

For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and critical audit matters reporting, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.

We could be an emerging growth company for up to five years following the year in which we completed our IPO, although circumstances could cause us to lose that status earlier.

We will remain an emerging growth company until the earlier of (1) March 31, 2024, (2) the last day of the fiscal year (a) in which we have total annual gross revenue of at least $1.07 billion or (b) in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior September 30th, and (3) the date on which we have issued more than $1.0 billion in nonconvertible debt during the prior three year period.

Even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company which would allow us to take advantage of many of the same exemptions from disclosure requirements including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.

We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions.

If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

Under the Jumpstart Our Business Startups Act of 2012, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies.

We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements applicable

to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation

requirements of Section 404 of the Sarbanes-Oxley Act and critical audit matters reporting, reduced disclosure obligations

regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding

advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.

could be an emerging growth company for up to five years following the year in which we completed our IPO, although circumstances

could cause us to lose that status earlier.

We will remain an emerging growth company until the earlier of (1) March 31,

2024, (2) the last day of the fiscal year (a) in which we have total annual gross revenue of at least $1.07 billion,

or (b) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held

by non-affiliates exceeds $700 million as of the prior September 30th, and (3) the date on which we have issued

more than $1.0 billion in non-convertible debt during the prior three year period.

Additionally, we are also a "smaller

reporting company,"

as defined in Regulation S-K.

We will remain a smaller reporting company if we have (1) less

than $250 million in market value of our shares held by non-affiliates as of the last business day of our second fiscal quarter

or (2) less than $100 million of annual revenues in our most recent fiscal year completed before the last business day

of our second fiscal quarter and less than $700 million in market value of our shares held by non-affiliates as of the last

business day of our second fiscal quarter.

If we are a smaller reporting company at the time we cease to be an emerging growth

company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.

Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial

statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have

reduced disclosure obligations regarding executive compensation.

We cannot predict if investors will find our common stock less

attractive because we may rely on these exemptions.

If some investors find our common stock less attractive as a result, there

may be a less active trading market for our common stock and our stock price may be more volatile.

Under the Jumpstart Our Business Startups

Act of 2012, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards

apply to private companies.

We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting

standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not

emerging growth companies.

As a result, changes in rules of U.S.

generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for:

generally accepted accounting principles or their interpretation,

the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our

financial position and results of operations.

Our amended and restated certificate of incorporation

provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between

us and our stockholders, which could limit our stockholders’

ability to obtain a favorable judicial forum for disputes with

us or our directors, officers, or employees.

Our amended and restated certificate of

incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for:

● any derivative action or proceeding brought on our behalf;

● any action asserting a breach of fiduciary duty;

· any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws;

● any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation, or our

amended and restated bylaws;

● any action asserting a claim against us that is governed by the internal affairs doctrine.

This exclusive forum provision may limit a stockholders ability to bring a claim in a judicial forum that it finds favorable for corporate disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees.

If a court were to find this exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.

Unregistered Sales of Equity Securities and Use of Proceeds.

This exclusive forum provision may limit

a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for corporate disputes with us or our

directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees.

If a court were to find this exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable

or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which

could seriously harm our business.

Unregistered Sales of Equity Securities and

Use of Proceeds.

Defaults Upon Senior Securities

3 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1A. Risk Factors